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Nicotine dependence is a major cause of tobacco-related illnesses. Although 
tobacco smoking continues to be the leading cause of preventable death, and 
although the harmful health effects resulting from it are well known, about 
20% of the global population continues to smoke. 
The addiction-causing substance in tobacco, nicotine, acts through 
dopamine pathways in the brain to produce several pleasurable experiences as 
a result of cigarette smoking. There are significant individual differences in 
how nicotine affects the body, and these differences in both the neurological 
and metabolic pathways of nicotine may determinate the degree of the 
subsequent nicotine addiction. Thus, both genetic and epigenetic factors 
related to nicotine metabolism and nicotine-induced dopamine metabolism 
can have an important role in influencing individual smoking behaviour. 
In this thesis, in addition to the potential nicotine metabolism-related 
gene, CYP2D6, a few selected genes acting in dopamine routes, namely, 
MAOA, MAOB, and SLC6A3, were genotyped for their several known variants, 
together with their selected DNA methylation sites. The polymorphisms and 
variations in DNA methylation levels of the genes included in the study were 
examined in relation to numerous smoking-related phenotypes in a well 
characterized study population of 1,230 Caucasians of Russian origin. The aim 
was to discover novel relations among several smoking-related phenotypes 
and methylation of the studied genes, as well as to verify some findings of the 
previous genetic studies on this topic. 
Our results indicate that the poor metabolic capacity associated-CYP2D6 
genotype, defined by the data derived from eight functional polymorphic sites 
of the gene, is related to cigarette consumption such that the carriers of this 
genotype have reduced risk of heavy smoking compared to the carriers of the 
extensive metabolism-associated genotype. We also discovered that the poor 
metabolizer genotype occurred more frequently with higher methylation 
values, which was found to be inversely related to heavier smoking. 
The studies on dopamine related genes revealed that the MAOA 1460 T 
variant allele, variable number of tandem repeat (VNTR) high-activity alleles 
(3.5R, 4R, and 5R), and MAOB int13 common G allele were more prevalent in 
female smokers than non-smokers. Additionally, the 5R allele of 30bp VNTR 
and the 9R allele of 40bp VNTR in SLC6A3 were associated with negligible 
smoking history. Moreover, although the carriers of 9R allele had somewhat 
higher Fagerström Test for Nicotine Dependence (FTND) scores, they were 
also more likely to successfully cease smoking.  
When methylation levels were explored, we found that current smokers 
were 2.5 times more likely to have increased SLC6A3 mean methylation levels 
compared to ex-smokers, whereas in MAOA and MAOB genes the methylation 
levels of single CpG sites were independently related to smoking behaviour. In 
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addition, some of the alterations in DNA methylation levels at individual CpG 
sites showed a high degree of dependence on the genetic polymorphisms 
studied, while others did not. As expected, age and gender were found to be 
major contributing factors in determining the DNA methylation levels. 
Our findings indicate that the CYP2D6-related metabolic capacity may 
be associated with cigarette consumption both through genetic and epigenetic 
mechanisms. Additionally, our results suggest that both the genetic and the 
epigenetic profiles of MAO and SLC6A3 genes modify the availability of 
dopamine and thereby shape the risk of developing nicotine dependence. Due 
to the complexity of nicotine addiction and the related phenotypes, more high-
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Anyone who begins to smoke risks becoming addicted to smoking for the rest 
of their lives. There are great variations among individuals in how easily they 
become smoking-dependent, how frequently they feel need to smoke a 
cigarette, how strong the withdrawal symptoms that they experience when not 
smoking are, and how successfully they can quit smoking if they wish. Smoking 
addiction alone can be a highly restrictive factor in one’s life, but the serious 
health problems associated with persistent smoking can also significantly 
reduce life expectancy and quality of life. 
Cigarette smoking continues to be the leading cause of preventable 
mortality and morbidity worldwide. Although the adverse health effects of 
tobacco consumption are well known, 20% of people globally continue to 
smoke cigarettes. Even if the proportion of smokers in the population has 
declined in recent decades [1], a significant number of smokers who wish to 
stop smoking, but have not succeeded in their attempts, remain smokers, 
mainly due to the addictive properties of nicotine. Since stopping smoking is 
always worthwhile from the perspective of individual health and the cost to 
society, more support is needed to facilitate smoking cessation efforts. There 
is, therefore, an urgent need for new information and new treatments to help 
smokers achieve a life without cigarettes.  
Genetics together with epigenetics offer new tools to utilize science to 
help in the battle against nicotine dependence and the resultant health issues. 
In particular, epigenetic research regarding smoking behaviour, which 
currently lags far behind studies on psychiatric disorders, could offer new tools 
to find novel treatments against nicotine addiction. 
In this thesis, we focused on genetic and epigenetic factors affecting 
individual differences in the development of nicotine dependence, that is 
genetic and epigenetic alterations potentially affecting 1) nicotine metabolism, 
and 2) dopamine availability, which may highly impact the addictive 





2.1 Evolution of smoking culture
When smoking was cool, cheap, legal, and socially acceptable 
In the United States, the consumption of tobacco products began to increase 
in the 1920s, and by the 1930s and 1940s almost every American man and 
women had embraced this new addictive habit. In Finland, more cigarettes 
were consumed in the 1920s than anywhere else in the world, and in the 1940s, 
after the end of the Second World War, in which most Finnish soldiers became 
smokers, 76% of men and 13% of women smoked [2].  
By the 1950s, smoking had become a global phenomenon, due to the very 
different attitudes towards smoking compared to today and the lack of 
sufficient knowledge on the harmful health effects of tobacco consumption. 
Smoking was considered cool and sophisticated, as seen in the example of 
Hollywood stars, who looked elegant when smoking cigarettes in movies and 
advertisements. Smoking was also promoted aggressively and became socially 
acceptable, even preferable, as there were only potential signs of its adverse 
health effects. 
In response to initial concerns about the possible negative health effects 
of smoking, one strategy of the tobacco industry was to directly advice 
physicians to convince consumers of the safety of smoking [3]. This led to a 
series of intensive and successful advertising campaigns that introduced 
smoking to people and suppressed their concerns about its risks to health. It 
was a true success story for the tobacco industry, especially in the United 
States, where 80% of adults smoked cigarettes. 
Although a link between lung cancer and tobacco smoking had already 
been discovered in the 1950s, it took decades to raise awareness among 
consumers of the harmful compounds in cigarettes and the consequential 
adverse health effects. The authorities in Finland took the first action to 
disseminate this information in the 1960s by announcing that smoking is 
hazardous to health. This was followed by banning the advertising of cigarettes 
in television, and an act to reduce smoking, which came into force in 1976. In 
the 1990s, 33% of Finnish men and 20% of women were smoking, meaning 
that while cigarette consumption had significantly decreased among men, it 
had become slightly more popular among women [2].  
Eventually, several decades after the successful introduction of tobacco 
products to the public, the harmful consequences of tobacco consumption 
began to unfold. Despite this, however, there were no immediate changes in 






The turning point 
In the 1990s, an EU directive banned smoking advertisements, and in 1995, 
Finnish legislation banned smoking in workplaces, except in bars and 
restaurants [4]. More restrictions were introduced in the beginning of the 
twenty-first century. For example, an EU directive came into force in 2001 that 
applied uniform warning labels to tobacco products [2], and in 2007, 
restaurants also became smoke-free in Finland. In addition, the Tobacco-free 
Finland 2040 project, which later became Tobacco-free Finland 2030, was 
established in 2008, to promote a tobacco-free lifestyle through various means 
[2]. 
In 2010, Finnish tobacco policy took a ground-breaking turn when the 
objective of the Tobacco Act of the time was redefined as ending the use of 
tobacco products, that is, so-called endgame thinking.  
Nowadays, the World Health Organization (WHO) Framework 
Convention on Tobacco Control (FCTC) provides a comprehensive framework 
for global tobacco control efforts. It is an important direction for tobacco 
product regulation, advertising, health warnings, price and tax issues, illicit 
trade, and programs for smoking cessation. In line with this direction, 
displaying tobacco products in sales was banned in Finland in 2012, and in 
2014, an EU directive came into force requiring tobacco packaging to include 
health warnings containing both image and text. In 2016, the updated version 
of the Finnish Tobacco Act [5] additionally covered nicotine products other 
than tobacco. The objective of the Act was also revised to ending the use of 
tobacco and other nicotine products by 2030. Finland is the only country in 
the world to legislate such an aim.   
Towards a tobacco-free society 
The Finnish efforts against smoking have been a success story: Smoking 
culture in Finland has drastically changed, especially at workplaces and in 
public places, and the latest statistics on Finnish smokers reveal that in 2015, 
16% of men and 12% of females consumed cigarettes. However, although the 
number of smokers has begun to radically diminish after achieving its 
popularity peak, due to the very long latency periods for the most serious 
health effects of smoking, Finnish society is currently struggling with the 
consequences of the peak years of smoking. In addition, new challenges have 
emerged in the efforts towards a tobacco-free Finland. For example, electronic 
cigarettes (e-cigarettes), snus (smokeless tobacco) and novel products such as 
heated tobacco products have rapidly gained popularity, putting a huge 
pressure on research and regulatory actions, which are lagging behind 
developments in the tobacco industry.  
Although e-cigarettes lack many of the harmful compounds typical of 
traditional tobacco products and have, therefore, been considered less 




cigarettes are yet available. In addition, worrying news of severe health 
consequences associated with their use have recently emerged. The potential 
dangers of e-tobacco usage (vaping) reached the headlines in the summer of 
2019 as people in the United States began to experience mysterious lung 
symptoms. In January 2020, the Centers for Disease Control and Prevention 
(CDC) reported that more than 50 people had died and more than 2,600 had 
become ill due to lung damage associated with vaping [6]. The likely cause was 
traced back to vitamin E, which is used as an ingredient in some e-cigarette 
liquids. So far, the situation in Finland is not as worrying as in the United 
States, as the use of e-cigarette products in Finland is still relatively minimal, 
and the products may also be somewhat different than in the United States.  
It also remains to be seen whether the claimed benefits of e-cigarettes for 
helping people stop smoking are true or are greater than the negative 
consequences among never smokers of providing an easier way to become 
addicted to smoking at younger age. 
2.2 Health consequences of smoking
Cigarette smoke includes over 5,000 chemical compounds, which include 
multiple carcinogens or probable carcinogens [7]. The known hazardous 
compounds in tobacco smoke include polyaromatic hydrocarbons (PAHs), 
tobacco-specific nitrosamines (NNK, NNN), aldehydes (acrolein, 
formaldehyde), carbon monoxide, hydrogen cyanide, nitrogen oxides, 
benzene, toluene, phenols, aromatic amines (nicotine, ABP [4-
Aminobiphenyl]), and harmala alkaloids [8]. The radioactive element 
polonium-210 is also  known to occur in tobacco smoke in addition to toxic 
metals, such as cadmium and mercury, which are naturally present in tobacco 
plants [9]. The amount of these toxic substances inhaled through tobacco 
smoke depends on the frequency, intensity, volume, and duration of the puff. 
Most pre-carcinogens in cigarette smoke require a metabolic activation 
process, in which they are converted to DNA adducts, to be able to cause their 
harmful effects by increasing the occurrence of somatic mutations, which can 
ultimately lead to development of cancer. This process is catalysed by multiple 
cytochrome P-450 (CYP) enzymes. Some carcinogens, however, can form DNA 
adducts without the metabolic activation. This process is followed by 
metabolic detoxification, which converts the carcinogenic metabolites into 
harmless compounds. The differences in the balance between the metabolic 
capacities of the enzymes involved in metabolic activation and detoxification 
of the carcinogens is therefore highly likely to significantly affect individual 
susceptibility to cancer [10].  
It is not surprising that regular smoking is followed in particular by 
various respiratory diseases; the inhalation of tobacco smoke primarily 
exposes the lungs to all the toxicants in the combustion product. However, as 




over the body, almost no organs in our body do not suffer from cigarette 
consumption. Consequently, smoking has major negative effects on the 
general health of smokers [11]. 
2.2.1 Malignant diseases
Cigarette smoking continues to be the leading cause of preventable mortality 
and morbidity worldwide; on average, 15% of all cancers are due to smoking. 
It has also been estimated to cause up to one in five deaths in the United States 
[12]. In addition, it is predicted that smoking triggers 90% of all deaths from 
lung cancer, which is undoubtedly the best-known smoking-related disease. 
For smokers who consume more cigarettes, use menthol flavoured tobacco, 
and have been smoking for a long time, the risk for lung cancer is significantly 
increased. Tobacco use also multiplies the risk of developing cancer in the oral 
cavity, oropharynx, and larynx. In other words, smoking or the use of other 
oral tobacco products for a long time is associated with an increased risk of 
cancer anywhere in the mouth or throat, but also in the head and neck area. 
Moreover, among smokers the incidence of bladder cancer is tripled, and 
stomach and pancreatic cancer doubled compared to non-smokers [11]. The 
most significant cancers, whose onset has been associated with smoking, are 
listed in Figure 1.  
2.2.2 Non-malignant diseases
In addition to malignant diseases, smoking also largely contributes to the 
development of several common non-malignant health problems, such as 
respiratory, cardiovascular, and bowel diseases (see Figure 1) [12-14]. 
As with lung cancer, smoking has been recognized as a major causative 
factor for chronic obstructive pulmonary disease (COPD), which includes 
emphysema and chronic bronchitis; lifelong smokers have 50% probability of 
developing COPD [13]. About 80 million people suffer from a moderate or 
severe form of COPD, and by 2020, it is estimated to be the third leading cause 
of mortality worldwide. In addition to smoking, passive smoking and 
environment pollutants can contribute to the risk for COPD by increasing the 
total toxic burden of the lungs. 
Smoking triggers an inflammatory response in the lungs and respiratory 
tract through reactive oxygen species. The resulting chronic inflammatory 
changes that develop in smokers lead to structural remodelling caused by 
constantly ongoing injuries and repair processes, which can persist in COPD 
patients even after smoking cessation. The early signs of COPD include noises 
in the chest, shortness of breath during physical activity, and coughing up 
mucus, resulting in difficulty breathing at rest. The symptoms worsen over 
time, and for the time being, there is no cure for this devastating disease. 
Smoking also increases the severity of several pulmonary conditions, 




Figure 1 Health risks for smoking. Adapted from Centers for Disease Control and 
Prevention website [14].
affecting approximately 300 million people worldwide, and its incidence is 
increasing. It is also responsible for 250,000 deaths per year.  
Asthma is characterized by a narrowing of the airways and the 
production of excess mucus, which makes breathing difficult and triggers 
coughing, wheezing, and shortness of breath. The severity of the symptoms 
can range from a minor ailment to life-threatening asthma, but with the 
appropriate treatment, the symptoms can be controlled. Although smoking 
affects the severity of the disease and increases morbidity and mortality, most 
asthma patients remain regular smokers [15, 16]. 
In addition to being a key factor in the development of severe disorders 
of the respiratory system, smoking also plays an important role in the 
development of cardiovascular diseases (CVDs), and it has been estimated to 
cause up to one in four deaths from CVDs [17]. It is noteworthy that even 
people smoking fewer than five cigarettes per day develop early signs of CVD. 




risk of CVD and can have heart attacks and strokes that lead to death and are 
caused by second-hand tobacco smoke [17]. 
The harmful chemicals of cigarette smoke cause the swelling and 
inflammation of blood vessels. This proinflammatory state and increased 
oxidative stress causing vasoconstriction can lead to several cardiovascular 
conditions, such as atherosclerosis, coronary heart disease, stroke, peripheral 
arterial disease, and abdominal aortic aneurysm. Moreover, tobacco smoke 
increases the release of catecholamine and activates the sympathetic nervous 
system, increasing the risk of ischemia and arrhythmia [18]. 
The numerous adverse health effects of smoking also include diminished 
fertility for both men and women; effects on the health of bones, teeth, eyes 
and skin; the triggering of type 2 diabetes; decreased immune function; 
rheumatoid arthritis; and gastrointestinal disorders including peptic ulcers 
and Crohn’s disease [11, 19]. 
2.2.3 Physiological effects of smoking cessation
There is no safe level of tobacco use, and people who quit smoking, regardless 
of their age, see substantial gains in life expectancy compared to those who 
continue to smoke. Although smoking causes long-lasting alterations in the 
body that can last for decades after quitting, smoking cessation also has some 
immediate positive health effects. Within a year or so after quitting smoking, 
the risks of heart attack, stroke, and several cancers are drastically reduced. 
Moreover, although the lungs have the hardest time during tobacco 
consumption, 10 smoking-free years halves the risk of lung cancer. Smoking 
cessation has also been associated with improved life expectancy [13, 14], and 
even quitting smoking only at the time of a cancer diagnosis has been 
associated with longer life expectancy compared to continuing smoking [20]. 
2.3 Nicotine dependence
2.3.1 Development of nicotine dependence
Although 70% of smokers have indicated their wish to quit [21], only 4–7% of 
smokers have been able to quit smoking without medication or treatment [22]. 
In addition, less than one third of smokers who could quit smoking with 
pharmacotherapy are able to stay smoke-free for at least 6 months [22]. It is 
also noteworthy that around 80% of smokers have started smoking before the 
age of 18 and that 20–25% became addicted to smoking and maintained their 
habit into adulthood [12]. 
Although other factors such as social and psychological factors also 
influence smoking behaviour, the major reason for the development of 
smoking dependence is the strong addictive properties of nicotine, a well-




tobacco plant and has been used for centuries for medical, social and 
ceremonial purposes, especially among Native Americans, [23]. It acts as a 
receptor agonist for most nicotinic acetylcholine receptors, causing the desired 
neurological effects in smokers, who try to maintain high levels of nicotine in 
their system to achieve enhancement of mood, relieve withdrawal symptoms, 
reduce stress and anxiety, induce feelings of pleasure, and improve ability to 
concentrate [12]. Nicotine is known as one of the most commonly abused 
drugs, due to its nature as causing both psychical and psychological 
dependence. 
2.3.2 The effect routes of nicotine
Neurotransmitter pathway 
After inhaling tobacco smoke, nicotine is transported to the brain in ten 
seconds through the lungs and bloodstream. In the brain nicotine binds to 
ligand-gated nicotinic cholinergic receptors (nAChRs), which usually bind 
acetylcholine. This results in the opening of the ion-channel, which allows the 
entry of Na+ and Ca2+ cations (Figure 2). This, in turn, leads to the activation 
of voltage-dependent calcium channels, causing an influx of calcium to nerve 
cells, and, eventually, the release of neurotransmitters [12, 24]. 





Neuronal nAChRs are widely distributed in the central and peripheral 
nervous systems [24, 26]. They consist of five subunits (Figure 2), namely, 
nine α (α2–α10) and three β subunits (β2–β4), the composition of which 
depends on the subtype and the location of the receptor in the brain. The 
nAChRs can be either homopentameric (consisting of either α or β subunits) 
or heteropentameric (consisting of both α and β subunits). The individual 
differences in the composition, anatomical location, and physiological 
properties of nAChRs are related to several physiological and behavioural 
qualities. The consequences of nicotine bonding also depend on the subtype of 
the nAChR, which may have an important role in the individual differences in 
smoking behaviour [24]. For instance, the receptor may include an α4 subunit, 
a determinant of its sensitivity to nicotine, which most often exists together 
with a β2 subunit, which has the strongest nicotine affinity, and some other 
adjusting subunits [12, 24]. 
The stimulation of nAChRs induces the release of various 
neurotransmitters in the brain such as dopamine, gamma-aminobutyric acid 
(GABA), noradrenaline, acetylcholine, glutamate, serotonin, and β-endorphin 
[27]. Dopamine is released in the nucleus accumbens area of the brain, 
providing the enjoyable and rewarding experience which is critical for the 
reinforcing effects of nicotine and other abused drugs (Figure 3). The 
dopamine release is facilitated by glutamate and inhibited by GABA, both of 
which are activated by nicotine–nAChRs conjugations [12, 24, 28]. 





While the increased release of serotonin appears to have antidepressant 
effects, it also causes a reduction in food intake and weight gain [29]. 
Moreover, after recurrent nicotine intake, the serotonin secretion is reduced 
and the number of serotonergic receptors increases, leading to depression and 
weaker stress tolerance upon smoking cessation. 
Long-term nicotine exposure also causes neuromodulation and 
neuroadaptation; smoking a single cigarette is enough to trigger release of 
several neurotransmitters in the brain (neuromodulation), and the continued 
presence of nicotine alters the structure and function of nicotine receptors 
(neuroadaptation). Consequently, the number of nAChR binding sites in the 
brain increases, possibly due to nicotine, which induces the desensitization of 
these receptors. Therefore, smokers tend to consume more cigarettes to avoid 
the presence of unbound receptors and maintain the desensitization state. 
These smoking-induced molecular events relieve the symptoms of craving and 
withdrawal, signs of severe nicotine dependence [12]. 
Metabolic pathways of nicotine 
The nicotine in the inhaled cigarette smoke is rapidly distributed throughout 
the system via blood circulation. The mean elimination half-life of nicotine in 
the human body is two hours, but it varies considerably among individuals 
(119  44 min) [30]. Seventy to 80% of the systemic nicotine is metabolized 
into cotinine by cytochrome P450 2A6 (CYP2A6), which is predominantly 
expressed in the liver (Figure 4). CYP2A6 also inactivates up to 40% of cotinine 
to its subsequent metabolite, 3’-hydroxycotinine (3HC). Because the 
metabolism of cotinine and 3HC is much slower than that of nicotine, the ratio 
of 3HC to cotinine has been commonly used as a marker for CYP2A6 activity 
[24]. 




Major inter-individual differences have been observed in CYP2A6-
related metabolic capacity: Women are, on average, faster metabolizers than 
men, and reduced metabolic capacity is more common in Asians and African 
Americans than in Caucasians and Hispanics.  
Another CYP-enzyme, CYP2B6, has also been suggested to have a role in 
the metabolism of nicotine [24]. A more important function of CYP2B6, 
however, lies in the metabolism of the antidepressant bupropion, discussed 
later. 
A third CYP-enzyme, CYP2D6, was also previously presumed to be 
involved in nicotine inactivation. However, in light of current knowledge, with 
the exception of the rare ultra-rapid metabolism (UM) phenotype, the 
CYP2D6 activity does not appear to be a major effector of individual’s nicotine 
metabolism capacity [31]. This may be because if the CYP2A6-related 
metabolic route functions in a normal efficient way, the role of the CYP2D6 
activity is of little relevance to the overall nicotine metabolism. However, 
CYP2D6 is involved in catalysing the effects of numerous drugs and 
xenobiotics and has been suggested to be important for the dopaminergic 
signalling pathway [32, 33]. Therefore, in addition to metabolism, CYP2D6 
may be involved in several other functions influencing the systemic effects of 
nicotine. 
2.3.3 Treatment of nicotine dependence
Since only a fraction of people have succeeded in quitting smoking without any 
medication or treatment, the right kind of treatment is essential in the battle 
against the addiction. However, the currently available methods have not been 
highly successful and only one fifth of smokers have tried pharmacotherapy 
when trying to eliminate cigarettes, and less than one third of those smokers 
who could quit smoking by using pharmacotherapy were able to stay smoke-
free for at least six months [22]. 
Nevertheless, the current methods approved by U.S. Food and Drug 
Administration (FDA) include nicotine replacement therapy (NRT) and the 
non-nicotine pharmacotherapies bupropion and varenicline. Nicotine 
replacement therapies, which include the transdermal patch, nicotine gum, 
inhalers, lozenges, and nasal spray, have doubled the abstinence rate 
compared to a placebo. Similar success in smoking cessation has been seen 
with bupropion, an antidepressant that acts both in the inhibition of 
dopamine-epinephrine reuptake and as an antagonist of nicotinic 
acetylcholine receptor. The third treatment, varenicline, is a medicine that 
mimics the effect of nicotine by acting as a partial agonist of the nicotinic 
acetylcholine receptor. It has been shown to prevent withdrawal and craving 
and has proven to be a greater facilitator of smoking cessation than the other 
available treatments [24]. 
In addition, nortriptyline is an antidepressant indicated for use in the 




been used among patients trying to quit smoking, although the FDA has not 
approved it for this purpose. Nortriptyline inhibits the reuptake of serotonin 
and noradrenaline, which increases the amount of neurotransmitters in the 
synapse. It also acts as an inhibitor of histamine, 5-hydroxytryptamine, and 
acetylcholine. However, due to serious adverse effects, nortriptyline is no 
longer used to treat young people [34]. 
The reason for the efficacy of antidepressants in the treatment of nicotine 
addiction can be quite easily reasoned. First, nicotine withdrawal may cause 
depressive symptoms, which may be relieved by antidepressants. Second, 
nicotine itself can act as an antidepressant, which leads to maintained 
smoking, in which case the medicine can be used to replace this effect. Finally, 
some antidepressants may have specific effects on the neural pathways related 
to nicotine addiction [35]. 
Finding individually tailored treatment for nicotine dependence could 
lead to success in smoking cessation. Aside from the fact that individual 
differences affect the metabolism of the drug, discovering the correct target for 
treatment based on a genetic (and epigenetic) profile, discussed in more detail 
below, would be useful in finding appropriate treatment for each individual. 
In other words, there are also individual differences in which treatment works 
the best. 
2.4 Genetics of nicotine dependence
Both genetic and environmental factors have been shown to play a crucial role 
in individual differences in smoking behaviour. According to several twin 
studies, genetic factors have a major impact (46–84%) on smoking initiation, 
persistence, intensity, and cessation. A substantial variability has also been 
observed in nicotine addiction and relapse times, which can be partly 
explained by genetic vulnerability [24, 36, 37]. However, similarly to 
individual differences in nicotine dependence development, genetic 
polymorphisms provide inadequate explanation for the differences in both 
short- and long-term systemic consequences following cigarette smoking. A 
research area of growing interest, epigenetics, could provide the link between 
genes and environmental factors that modify an individual’s gene expression, 
thereby leading to the development of nicotine dependence and subsequent 
disease development. 
2.4.1 Genes – the basis for individual differences
All inherited traits that, together with the environmental factors, make every 
individuals unique are contained in the genes packed in the DNA 
(deoxyribonucleic acid), which is arranged in 23 chromosome pairs (total of 
46 chromosomes) in almost every human cell; one set of the 23 chromosomes 




germ cells, which contain only one set of 23 chromosomes, and red blood cells, 
which do not contain any DNA.  
Two of the chromosomes, referred to as the X and Y, are the so-called sex 
chromosomes, and their combination determines the gender of the individual; 
normally, females have two X chromosomes while males have an XY pair. 
According to current knowledge, the human genome contains 
approximately 20,000 protein-coding genes, nearly all of which are packed 
into chromosomes in the nucleus; exceptionally, however, 13 proteins are 
encoded by genes located in the mitochondria.  
At the beginning of human life, the chromosomes contained in the germ 
cells of the mother and the father combine in a fertilized egg cell to form the 
23 pairs of chromosomes that encompass a unique mixture of genes. When the 
cell begins to divide, the DNA divides with it. Thus, the genetic material 
remains the same in every cell, even after multiple cell divisions. However, 
significant differences between the cells emerge in the course of the cell 
divisions due to tissue-specific gene expression, which means that a different 
set of genes are turned on or off in the cells, depending on what organs they 
have been programmed to form. In addition, mutations in the genome may 
occur during the cell divisions. 
The DNA strand is constructed of nucleotides, which consist of sugar-
phosphate molecules attached to one of the four bases, namely, adenosine (A), 
thymine (T), guanine (G), and cytosine (C), arranged in a specific order in a 
double helix conformation to construct the genetic code. The order of these 
four bases is 99.9% identical in all humans. The specific regions of the double-
stranded DNA form genes ranging in length from 500 to more than 2 million 
base pairs.  
Genes contain introns and exons, both of which are first copied into pre-
mRNA (messenger ribonucleic acid) in a process called transcription. During 
the subsequent RNA splicing stage, however, introns are edited out, and exons 
joined to form the contiguous coding sequence, which is eventually translated 
into a protein product. Although introns do not encode proteins, they are 
integral to the regulation of gene expression. Some intronic sequences act as 
enhancers or repressors of transcription by the action of various proteins that 
bind to these sequences. Introns also act as spacers between coding gene 
regions, facilitating the alternative splicing of genes, thereby enabling the 
generation multiple proteins from a single gene. 
Variations in the gene sequences, which may result in significant 
variances in their ultimate protein products, is the prime cause of all the 
inherited inter-individual differences. The variant form of a gene, having a 
change in any specific site of the gene, is called a variant allele. An allele is one 
of a pair of genes that appear at a specific location on a certain chromosome 
and control the same characteristic. Normally, every individual has two alleles, 
one from each parent. Thus, one may have two similar, homozygous, alleles or 




An alteration in even a single nucleotide, called single nucleotide 
polymorphism (SNP), may have a crucial effect on gene transcription. Some 
SNPs do not have notable consequences, and some SNPs cause trivial 
differences among individuals, such as the ability to metabolize lactose, 
whereas a mutation in some sites may cause a serious health problem or 
disability. Other alterations in the DNA can have similar consequences, such 
as insertions or deletions of one or more nucleotides, and repetitive DNA 
sequences. The latter alterations include highly polymorphic variable number 
or tandem repeats (VNTRs). In VNTRs, the repeat sequence, whose length can 
vary from 10 to 100 base pairs, is normally repeated 2–100 times, and 
sometimes even thousands of times. They also include short tandem repeats 
(STRs), in which the repetitive unit, whose length varies between 1 and 6 base 
pairs, is repeated on average 100 times [38, 39]. 
Although there are some single alterations in DNA sequence that can 
produce visible variations in the phenotype, most human traits are due to a 
number of genes whose expression is affected by environmental factors. This 
is called multifactorial inheritance. 
2.4.2 Examination of the genetics of smoking behaviour
Nicotine addiction is a complex trait to study due to the multiple genetic and 
environmental factors affecting this phenotype. There are a few options of how 
to find chromosomal regions and genes that contribute to a specific phenotype 
of nicotine dependence. Genome-wide association studies (GWAS) are 
nowadays commonly used to identify novel susceptibility genes for various 
diseases. The lack of preconception and usage of large sample size also  makes 
GWAS a powerful tool for discovery of novel genetic variants related to 
nicotine addiction [24]. 
 The current trend in genetic studies is to conduct meta or pooled 
analysis, in which the data of several GWAS is combined. This approach 
benefits from a massive amount of data and enables the identification of 
specific patterns among multiple study results. However, it is difficult to find 
sufficiently similar study setups, which can be reasonably combined into single 
database. 
Also, the candidate gene studies are useful in exploring the potential 
genetic factors in development of nicotine addiction. In these studies, the 
candidate genes are chosen based on the knowledge about the neurobiological 
and metabolic pathway of nicotine, or the information gained from the GWASs 
or previous reproducible candidate genes studies. The SNPs of the selected 
genes are studied by comparing unrelated groups in case-control studies or 
members of family units in family-based studies [24].  
In addition to studies based on single or a few candidate genes, the 
concurrent influence of multiple genetic variants on nicotine dependence is 
currently being investigated. These studies focus on finding associations 




pathway. In all these studies, consistent determination of the phenotype and a 
large enough sample size are important to obtain reliable results and to avoid 
recurring false positive results [24]. 
The effects of nicotine on nicotinic acetylcholine receptors, dopamine 
release, and dopamine metabolism are considered the major pathways behind 
tobacco dependence [40]. Below, the current knowledge on the genetic 
variations of these pathways associated with different smoking behaviour 
related phenotypes (see Table 1) is presented along with individual differences 
in the response to current treatments of nicotine addiction (see Table 2). 
 
Table 1. Most studied genetic polymorphisms related to smoking phenotypes























rs2236196 smoking cessation [51]
CHRNA6 and 
CHRNB3












DRD2/ANKK1 Taq1A rs1800497 smoking behaviour [57, 58]



















OPRM1 A118G variant smoking reward, 
reinforcement
[65, 69]




DBH rs3025343 smoking cessation [74]
TPH C218A and C779A smoking initiation
nicotine dependence
[75-78]
SLC6A4 a 44-bp insertion 
(allele L) or deletion 
(allele S)
nicotine dependence [79-81]
CYP2A6 *2, *4 (null activity 




*2, *4, *9, *12 CPD, nicotine addiction [50, 83, 86-93]
*2 smoking cessation [94]








nicotine addiction [52, 95, 96]
BDNF rs6265 (Val66Met) tobacco consumption
cigarette smoking
[52, 97-100]
CPD= Cigarettes per day
Genetic variation in nicotinic acetylcholine receptor genes 
Several GWAS- and pathway-based association studies have revealed a link 
between the genetic variants in the CHRNA5-CHRNA3-CHRNB4 gene cluster 
encoding three nicotinic acetylcholine receptor subunits (α5, α3, and β4, 
respectively) and nicotine dependence and heavy smoking [41-45]. Moreover, 
the α5 D398N variant in the α5-α3-β4 complex has been suggested to result in 
lower Ca2+ permeability, which reduces nicotine signalling and could thus lead 




Table 2. Genetic polymorphisms and response to treatment of nicotine
addiction 
Gene Polymorphism Treatment Effect of the variant 




CHRNA5 rs518425 varenicline better response [101]
rs588765 NRT better response [102]









varenicline better response [101]
rs2236196 NRT better response [51]
CHRNB2 rs2072661 bupropion worse response [104]
NRT worse response [105]
rs3811450 and 
rs4262952
varenicline better response [101]





bupropion better response [106]
CYP2A6 carriers of fast 
metabolizers
NRT better response [107]
carriers of slow 
metabolizers
bupropion better response [108]
CYP2B6 *5, *6 bupropion better response [109]
rs1808682 bupropion better response [101]
rs8109525 varenicline better response [101, 110]
COMT rs4680 Met/Met 
genotype
NRT better response [111, 112]
NRT= Nicotine replacement therapy
Although many studies have failed to link separate SNPs in the 
CHRNA5-CHRNA3-CHRNB4 gene cluster to the ability to quit smoking or 
experience severe withdrawal symptoms, in one study, the CHRNB4 
rs11072768 SNP was found to be related to the ability to cease smoking [43]. 
In addition, some CHRNA5-CHRNA3-CHRNB4 haplotypes have been 
associated with the failure to quit smoking and with withdrawal severity [24, 




The associations between smoking persistence and SNPs in CHRNA5 
(rs12915366) and CHRNA3 (rs12914385) genes [46], in turn, supported the 
previous findings about the regions of both the SNPs that were associated with 
nicotine dependence in both African Americans and European Americans 
[45]. Similarly, SNPs in the CHRNA5-CHRNA3-CHRNB4 gene cluster were 
associated with smoking behaviour in a Korean study population [43]. 
Recent studies on the role of the CHRNA5-CHRNA3-CHRNB4 cluster in 
nicotine dependence and smoking behaviour have also taken into account the 
effects of treatments. For example, smokers treated with varenicline had 
better abstinence rate if they carried the CHRNA5 rs518425 variant allele 
[101]. The variant allele of CHRNA3 rs1051730 SNP was also found to be 
weakly associated with a poor smoking cessation rate among open-label 
nicotine transdermal patch treated smokers [103]. However, another study 
observed an association between this allele and increased abstinence in NRT, 
as well as between the variant allele of CHRNA5 rs588765 SNP and increased 
abstinence in NRT [102].  
The combination of α4 and β2 subunits, which is the most common 
combination in the high-affinity nicotinic receptors in the brain, has also been 
associated with individual smoking behaviour. The α4 subunit is expressed in 
almost every dopaminergic and GABAergic neurons region affecting 
dopamine release into the nucleus accumbens area, that is, the pleasure centre 
in the brain, and the CHRNA4 haplotypes have been associated with nicotine 
dependence and heavy smoking in several studies using different approaches 
[24, 48-50]. Moreover, the CHRNA4 rs2236196 SNP has been associated with 
the ability to quit smoking [51]. 
Because the effect of varenicline is based on its strong affinity to an α4-
β2 receptor, which stimulates dopamine release but prevents nicotine binding 
to the receptor, the varenicline treatment has been expected to work best in 
smokers with a decreased dopamine-availability-related genotype [29]. 
Reinforcing this, a few SNPs in the CHRNA4 gene (rs2236196, rs3787138, and 
rs6062899) have been associated with the success of abstinence among 
smokers treated with varenicline [101]. One of these SNPs (rs2236196) affects 
the binding site of iron-responsive element (IRE), which regulates the genes 
participating in the function of central nervous system (CNS). Thus, the results 
may indicate that the genetic variation of the CHRNA4 gene contributes to the 
differences of nicotine sensitivity and quitting success, when NRT, that 
reaches CNS rapidly, is used [24, 51].  
The SNPs in the CHRNB2 gene have also been associated with smoking 
cessation success; the rs2072661 SNP is associated with the success of 
bupropion [104] and NRT treatments [105], and the rs3811450 and rs4262952 
SNPs with varenicline treatment [101]. 
The α6 subunits, often expressed with β3 subunits, are, in turn, located 
in the brain area, in which nicotine induces dopamine release. Mouse studies 
suggested that the α6 subunit has some significance in nicotine withdrawal 




CHRNA6 and CHRNB3 genes have been associated with nicotine addiction 
and individual responses to nicotine [52-54]. A meta-analysis of GWASs also 
found an association between CHRNA6 and CHRNB3 and the number of 
cigarettes smoked per day (CPD) [50]. 
One of the most widespread nAChRs components in the CNS, α7 subunit, 
participates in facilitating neurotransmitter release and has therefore been 
linked to several nicotine-induced symptoms. Studies with knock-out mice 
aiming to enlighten the role of the α7 subunit in nicotine dependence and 
withdrawal have, however, produced controversial results. In addition, only a 
few human studies have found associations between CHRNA7 genotype and 
smoking behaviour; the CHRNA7 SNPs were associated with the severity of 
nicotine dependence in Jewish females [55], and an association was found 
between rs6494212 SNP and abstinence among varenicline-treated smokers 
[101]. 
Finally, the CHRNB1 gene encoding β1 subunit has also been linked to 
the nicotine addiction; the rs2302763 SNP, and the haplotype of three 
different SNPs in the CHRNB1 gene have been observed to be significantly 
associated with nicotine dependence [56]. 
Genetic variation in dopamine availability 
Some candidate genes encoding dopamine receptors and transporters, GABA, 
and opiate and cannabinoid receptors have also been associated with smoking 
behaviour. For instance, the outcomes of studies on polymorphisms of 
dopamine receptor genes DRD1, DRD2, DRD4, and DRD5 have suggested that 
decreased dopamine receptor expression causing variants of these genes 
increases the risk of both beginning smoking and doing so at an earlier age on 
the one hand and of being unsuccessful in quitting on the other hand [57-62]. 
This could be due to the reduced number of dopamine receptors, which leads 
smokers to try to compensate by enhancing nicotine intake, thereby increasing 
the dopamine levels in the brain [24]. In addition, these studies have led to the 
suggestion that individuals concurrently carrying variant alleles of both DRD2 
(A1) and CYP2B6 (*5) genes achieve the highest abstinence rate when treated 
with bupropion [106]. As a disadvantage, the  DRD2/ANKK1 A1 allele seems 
to increase the side-effects of bupropion [113]. 
The SLC6A3 (solute carrier family 6, previously known as DAT or DAT1, 
dopamine transporter) acts in dopamine neurotransmission by recycling the 
synaptic dopamine back to the presynaptic neurons. This crucial role in 
dopamine availability makes SLC6A3 an attractive candidate gene for studies 
on nicotine addiction.  
There is a common 40-base-pair VNTR polymorphism (rs28363170) 
located in the 3’-untranslated region (3’UTR) of the SLC6A3 gene whose 
repetitive unit is repeated 3–12 times. The most frequent alleles with 9 (9R-
allele) or 10 (10R-allele) repeats have previously been found, although 




9R-allele which has been associated with smoking cessation and treatment 
responses, although with some contradictory results [63, 114, 115] [64-66]. 
Additionally, a much less studied 30bp VNTR (rs3836790) in intron 8 of 
SLC6A3 has been reported to affect mRNA expression along with associations 
with cocaine abuse [116, 117]. 
Monoamine oxidases (MAOs) exist in two isoforms, MAO-A and MAO-
B, which catalyse the oxidative deamination of amines, such as dopamine, 
noradrenaline, and serotonin. MAO-A has an important role in the control and 
regulation of neurotransmitters, which moderate, among other things, mood, 
concentration, pleasure, and arousal. These neuronal pathways are stimulated 
by nicotine together with other compounds in cigarette smoke. For instance, 
MAO activity is significantly inhibited in tobacco smokers [68, 118, 119]. 
Accordingly, the MAOA allele, consisting of four 30bp repeat units (4R), has 
been related to nicotine dependence and to the probability of becoming a 
smoker [67, 68]. The MAOA is also the most studied gene in psychiatry [120], 
and the VNTR variants of the gene, resulting in lower gene transcription, are 
related to alcoholism and to antisocial and aggressive behaviour [120-122]. 
Moreover, the gene encoding the opioid receptor mu, OPRM1, has been 
found to contribute to the development several addictions through the 
dopamine system. In addition to the role discovered in opioid and alcohol 
addictions, the OPRM1 118G variant allele has been associated with smoking 
reward and reinforcement [65, 69]. 
In addition, some other genes encoding for enzymes involved in the 
synthesis and metabolism of dopamine have, although with limited data, been 
associated with smoking behaviour. These include the gene variations of TH, 
which converts tyrosine to dopamine, and DDC, which catalyses, for example, 
conversions to dopamine and serotonin [70-73]; these variations have been 
associated with nicotine addiction. In addition, the gene variants of DBH, 
which catalyses the conversion from dopamine to noradrenaline, and COMT, 
which catalyses the methyl group transfer to catecholamines such as 
neurotransmitters, have been associated with smoking cessation; the COMT 
genotype has also been found to predict a better response to NRT treatment 
[74, 111, 112]. 
Genetic variation in serotonin availability 
Genes affecting the serotonin pathway have also been investigated for elevated 
serotonin levels resulting from nicotine-nAChR interaction. Variation in the 
tryptophan hydroxylase (TPH) gene, involved in serotonin biosynthesis, has 
been associated with smoking initiation and with an earlier onset of nicotine 
dependence [75-78]. A link has also been found between increased 
neuroticism in nicotine dependence and the short (S) allele of an 
insertion/deletion polymorphism in the upstream regulatory region of the 
serotonin transporter (SLC6A4, previously 5-HTT) gene, resulting in lower 




long (L) allele, associated with higher expression levels of SLC6A4, was found 
to be significantly more prevalent among smokers than non-smokers [80]. 
Nonetheless, lower serotonin re-uptake seems to affect numerous behavioural 
traits that have been associated with, for example, increased nicotine 
dependence and unsuccessful smoking cessation [29]. 
Importantly, the individual differences in serotonin availability may 
affect the success of smoking cessation treatment, since nortriptyline, a 
medicine used to help achieve complete abstinence, inhibits the re-uptake of 
serotonin. However, studies considering the impact of nortriptyline among 
smokers with differences in the polymorphisms in genes involving serotonin 
pathway are yet lacking. 
Genetic variation in nicotine metabolism 
As discussed earlier, CYP2A6 metabolizes the vast majority (70–80%) of the 
systemic nicotine. To date, few relatively common reduced- and null-activity-
associated alleles of the CYP2A6 gene have been found; CYP2A6*2 and *4 
denote the null activity alleles, and CYP2A6*9 and *12 denote the reduced 
activity alleles. The reduced and null activity alleles have been shown to be 
more prevalent in non-smokers than smokers [82-85]. Moreover, smokers 
with the reduced or null activity CYP2A6 alleles tend to smoke fewer cigarettes 
and to be less addicted to nicotine compared to smokers with the normal 
activity alleles [50, 83, 86-93]. Smokers with the CYP2A6*2 allele have also 
been reported to succeed at quitting smoking twice as often as smokers with 
two normal activity alleles [94]. In addition, the normal activity alleles have 
been shown to be associated with earlier nicotine dependence development 
and more severe withdrawal symptoms. The latter association was found to be 
even stronger among smokers using NRT, such as transdermal patches [107]. 
In recent years, studies have been expanded to investigate the effect of 
CYP2A6 gene polymorphisms on responses to medical treatments. Although 
the outcomes of the studies indicate that the carriers of decreased nicotine-
metabolism-associated CYP2A6 alleles have generally better abstinence rates, 
the fast metabolizers seem to respond better to NRT treatment [29, 110]. 
Carrying the decreased CYP2A6-metabolism-associated alleles also appears to 
dilute the effect of bupropion treatment [29]. 
Also, the variation in the gene of bupropion-metabolizing enzyme 
CYP2B6 has been shown to have an impact on bupropion treatment [109]. The 
CYP2B6*5 and *6 variant alleles have been associated with slower bupropion 
metabolism, and smokers carrying one of these allelic variants seem to be 
more successful in achieving abstinence with bupropion treatment compared 
to a placebo. By contrast, no beneficial effect for this substance was observed 
among individuals with the normal-activity-associated CYP2B6*1 allele.  
In addition, the CYP2B6*4 allele is associated with higher 3HC/cotinine 
ratios in smokers with reduced CYP2A6-related metabolic capacity, and the 




and K262R variants, is associated with a more rapid nicotine and cotinine 
metabolism rate [24]. 
However, it has been questioned whether the higher abstinence rate 
associated with the CYP2B6*5 and *6 variant alleles in fact results from their 
effect on nicotine rather than bupropion metabolism. Although there is no 
decisive evidence about the importance of the CYP2B6 genotype in nicotine 
metabolism, some studies have suggested that it also contributes in this 
context [24]. Moreover, this contribution might be more easily evidenced if it 
was not masked by the CYP2A6-related metabolism.  
A third potential nicotine-dependence- and smoking-behaviour-
affecting CYP-enzyme is CYP2D6. Although several studies have failed to 
associate the other CYP2D6 genotypes with nicotine metabolism, the UM 
capacity, resulting from a duplication of the functional CYP2D6 gene, may 
influence the nicotine inactivation process, although with a minor 
contribution [29, 31]. In addition, the UM-related genotypes were found to be 
more common among heavy smokers [33]. As for the other CYP2D6 
variations, the possibility remains that undisturbed CYP2A6 activity covers 
their potential more modest effects on nicotine metabolism. 
CYP2D6 is the second most important drug metabolizing enzyme after 
CYP3A4. It is involved in 25% of metabolism of all prescribed drugs [123]. The 
functional genotypes of CYP2D6 have been shown to have wide effects in 
individual drug metabolism capacity, including the metabolism of 
nortriptyline, an antidepressant also used for nicotine addiction treatment 
[32, 124].  The current recommendations for antidepressant treatment even 
advice that the CYP2D6 genotype is determined prior to prescribing the dose.  
Other genetic variations  
To date, the GWASs have mainly revealed new genes related to different 
aspects of smoking behaviour that are not clearly involved in either nicotine 
neurotransmission or metabolism. These genes include NRXN1 (neurexin 1) 
and BDNF (brain derived neurotrophic factor). 
The NRXN1 gene encodes a cell surface receptor acting in the CNS and 
has previously been associated, for example, with susceptibility to 
schizophrenia. Recently, several studies have also linked many NRXN1 gene 
variants to nicotine addiction [52, 95, 96]. 
The BDNF gene, in turn, encodes a member of the nerve growth factor 
family of proteins that acts on neuronal survival in the adult brain. Several 
studies have found a connection between BDNF genotypes and tobacco 
consumption [46, 52, 97-100].  
Overall, the effect of separate known gene variants on different smoking 
phenotypes is relatively small; it is the sum of multiple genetic variants, 





2.4.3 Phenotypes of smoking behaviour
As nicotine dependence and smoking cessation ability exhibit unique genetic 
backgrounds, they must be considered as two distinct phenotypes in studies of 
different aspects of smoking behaviour. Well-defined phenotypes are 
therefore required in these studies, though it has been a great challenge. For 
instance, one measure of nicotine addiction is the widely used Fagerström Test 
for Nicotine Dependence (FTND), which collects information about smoking 
habits to estimate the strength of the smoking addiction [125]. The test is, 
however, a rather poor predictor of quitting success and withdrawal 
symptoms.  
Most of the recent genetic studies on this topic have focused on the 
smoking cessation phenotype, and comparisons between former smokers and 
current smokers have been used with some success [24]. The definition of 
smoking cessation phenotype can also be based on the ability to quit among 
treatment seeking smokers. However, the term “nicotine dependence” is also 
used when comparing groups of current and former smokers, even though this 
perspective is different from that used in the FTND. The inconsistency in 
terminology and the diversity of phenotypes related to smoking-behaviour 
studies makes it more difficult to obtain consistent and comparable results. 
2.5 Epigenetics of nicotine dependence
Epigenetics refers to heritable changes affecting gene expression without 
alterations in the DNA sequence. The most common epigenetic modifications 
are histone modification, epigenetic related non-coding RNAs (ncRNAs), and 
DNA methylation.  
Histones are components of a nucleosome, which consists of DNA 
wrapped around a histone octamer. The histone modifications are post-
translational and include methylation, acetylation, phosphorylation, 
ubiquitylation, and sumoylation. Histone acetylation is the most studied 
chromatin modification in the field of drug abuse and generally increases gene 
activity [126].  
Meanwhile, ncRNAs refer to expressed RNAs that are not translated into 
protein and have an important role in cell regulation. The ncRNAs most 
studied as epigenetic modulators are microRNAs (miRNAs), which generally 
bind to a specific target messenger RNA by a complementary sequence to 
either induce cleavage or degradation, or block translation. This may be done 
in conjunction with a feedback mechanism involving DNA methylation, which 
is the most studied epigenetic modification (see below). 
DNA methylation, that is, the attachment of a methyl group to cytosine, 
next to guanine, affects gene expression and is essential to cell differentiation, 
imprinting, and X-chromosome inactivation [126]. Moreover, it has proven to 




DNA methylation is a quantitative trait, a proportion of methylated DNA 
strands. CpG islands (CGI) are regions rich in cytosine-guanine-dinucleotides 
often located in gene promoter areas and repetitive DNA elements, or in gene 
bodies. Promoter CGIs are mainly unmethylated (hypomethylation), whereas 
CGIs in gene bodies and repetitive DNA elements are more frequently 
methylated (hypermethylation). The unmethylation of gene promoters and 
the methylation of gene bodies have been suggested to be associated with 
increased DNA transcription [126, 127]. 
Interestingly, different tissues show high similarity in their DNA 
methylation patterns: Only 5–15% of CpGs represent tissue-specific 
methylation. These differentially methylated CpG sites exist more often in 
developmentally distant tissues, such as liver and brain tissue, than 
developmentally close tissues, such as different types of lymphocytes [127]. 
However, some single CpGs may also be methylated in a cell-specific manner, 
and differences have been found even among lymphocytes [128]. Overall, the 
methylation patterns differ in some parts among tissues and cells, but in a 
gene-specific and a single-CpG-site-specific manner. 
Moreover, environmental factors may induce alterations in DNA 
methylation patterns, some of which may remain long after environmental 
exposure disappears, though most of the changes are reversible. Alternatively, 
genetic factors may determine DNA methylation patterns with varying levels 
of contribution across single CpGs, thus explaining some of the inter-
individual differences. Additionally, both environmental and genetic factors 
behind methylation-derived gene expression may influence the systemic 
response for further environmental stimuli. Thus, genetic, environmental, and 
epigenetic factors compose an interacting circle that produces an individual 
combination of protein products [127, 129]. 
2.5.1 Epigenetic consequences of tobacco smoking
Smoking is a well-warranted target for epigenetic studies because tobacco 
smoke is considered to be one of the most powerful environmental modifiers 
of DNA methylation; cigarette smoking has been shown to decrease global 
methylation, leading to increased expression of some genes, which in turn may 
cause several adverse effects and can also change the smoker’s behaviour.  
The smoking-induced methylation modifications occur in multiple 
tissues and can differ significantly among the target tissues. These methylation 
changes can be observed after as few as nine months smoking [130]. For 
example, in one study, smoking was found to induce long-lasting epigenetic 
modifications, which in particular affected the expression of MAOB gene and 
offered an explanation for the high MAO-B protein concentration remaining 
long after the cessation of smoking [129]. 
Nicotine, has been shown to have direct effects on methylation status; 
one study found nicotine both to cause genome-wide methylation changes by 




methylation levels of GABAergic interneuron genes through a gene-specific 
methylation change [131]. In addition, a single CpG site has shown sensitivity 
to nicotine, resulting in differences in gene expression, while the attachment 
of a methyl group interferes the binding site of a transcription factor [132]. 
In recent years, several studies, including epigenome-wide association 
studies (EWAS), which have become the research trend in this field, have also 
linked tobacco smoke exposure to the epigenetic modifications, such as altered 
expression of miRNAs and chromatin and histone modifications, and related 
them to individual vulnerability to COPD or cancers, for example, by affecting 
gene expression in inflammatory cells [133]. 
2.5.2 Link between DNA methylation levels and mental disorders and 
addictions
The epigenetic modifications in dopamine pathway genes have been found to 
affect the risk of mental illnesses such as Alzheimer’s disease, schizophrenia, 
and some personality disorders (Table 3) [134-136].  
In the context of common psychiatric illnesses, the MAO genes and their 
methylation levels have been shown to be of great importance. Abnormalities 
in MAOA promoter methylation have been associated with paranoid 
schizophrenia [134], post-traumatic stress disorder (PTSD) [137], and 
antisocial personality disorder [138] in males, and with panic disorder [139], 
acrophobia, and depression in females. In addition, MAO-A is 
pharmacologically inhibited by several antidepressants and the methylation of 
specific CpGs in the MAOA promoter region may have an impact on the 
response to treatments with serotonin reuptake inhibitors [140]. 
Aside from MAO genes, the methylation of several other 
neuropsychiatric genes (COMT, DAT1, GABRA1, GNB3, GRIN2B, HTR1B, 
HTR2A, 5-HTT, NOS1, NR3C1, TPH1 and TH) has also been of interest. Of 
these, the DNA methylation levels of HTR2A, NR3C1, and soluble COMT have, 
in addition to MAOA and MAOB, been associated with borderline personality 
disorders [135]. 
Moreover, SLC6A3 methylation levels have been related to individual 
risk of developing alcoholism, PTSD, and eating disorders [114, 141, 142]. In 
the latter disorder, a connection between the hypermethylation of promoter 
SLC6A3 and the up-regulation of the gene’s expression has also been 
discovered. In addition, hypermethylation of the DRD2 promoter region 
showed association with anorexia nervosa [141], and methylation of the 
promoters of the DRD gene network overall has been suggested to be involved 
in the increased risk for schizophrenia [136]. 
Because addictions are counted as a type of psychiatric disorder, there is 
likely to be a similar epigenetic vulnerability behind nicotine addiction and the 
above-mentioned mental illnesses. Nicotine dependence is an example of drug 




characterized by withdrawal and compulsive drug-taking and -seeking 
behaviour despite the associated adverse consequences [143].  
Approximately 50% of the risk of addiction is proposed to be explained 
by genetic factors, with an equal contribution being attributable to 
environmental factors. However, the repeated use of an addictive substance 
causes alterations in gene expression leading to long lasting behavioural and 
structural changes. These changes in gene expression levels could be explained 
by epigenetic mechanisms. In particular, the gene expression profile in the 
reward circuitry of the brain has been shown to be altered by repeated 
exposure to several drugs of abuse. However, studies on the epigenetics of 
smoking behaviour have so far lagged far behind the epigenetic studies of 
other addictions and neurological diseases.  
One should also bear in mind possible genetically derived methylation 
patterns, which may affect the response of the body to environmental stimuli. 
Epigenetic status may in fact modify one’s vulnerability to becoming addicted 
to nicotine in a similar manner as genetic polymorphisms. Only a few previous 
studies have taken this perspective into account in examining the influence of 
methylation on smoking behaviour. Therefore, the main task in epigenetic 
studies in the field of addiction research lies in the difficulty in revealing the 
true cause and consequence relationships [143, 144]. 
For instance, although MAOA is the most studied gene in psychiatry from 
the perspective of epigenetics [120], only a few previous studies have evaluated 
the potential relation between the methylation of the MAOA gene and 
smoking. Moreover, in these studies, smoking was purely considered to be the 
cause of epigenetic alterations, and not vice versa. 
One of the studies found a link between decreased MAOA promoter 
methylation and nicotine and alcohol dependence in women [145]. Another 
study both repeated these results and, as a novel finding, associated MAOA 
methylation with current smoking status [146]. Moreover, the methylation of 
the promoter region of COMT, whose genetic variant has previously been 
related to nicotine dependence, has been associated with tobacco smoking; the 
methylation degree of COMT promoter was observed to be significantly higher 
among smokers than non-smokers [147]. However, these studies have mainly 
focused on the effects of tobacco smoke exposure, instead of studying the 
different aspects of nicotine addiction.  
Table 4 lists the main findings of studies on smoking behaviour related 
alterations focusing on the examination of DNA methylation in this context. 
Subsequent to the first epigenetic studies on smoking behaviour and MAO 
genes, the alterations in the methylation of F2RL3 (F2R like thrombin or 
trypsin receptor 3), AHRR (aryl-hydrocarbon receptor repressor), and GPR15 
(G protein-coupled receptor 15) genes have been related to smoking 
background in several studies [130, 148-154]. Nevertheless, the molecular 
pathway (described briefly below) of these genes also suggests that the 
alterations in their methylation could result from a response to smoking 




methylation levels could be used both as biomarkers for smoking and to 
predict the susceptibilities to smoking-related illnesses. 
The F2RL3 gene encodes for protease-activated receptor 4 (PAR4), 
which is involved in several cardiovascular mechanism and inflammation, 
which in turn are common for a smoking-induced pathology. Thus, DNA 
methylation alterations in this gene could offer a mechanistic link between 
smoking and cardiovascular diseases.  
AHRR, in turn, encodes a protein that is involved in the regulation of cell 
growth and differentiation and the modulation of the immune system. AHRR 
is also a known tumor suppressor that can mediate detoxification of the 
carcinogenic compounds in tobacco smoke [154]. Thus, changes in DNA 
methylation that affect AHRR expression may be related to the smoker's 
ability to eliminate the harmful compounds in tobacco smoke [127]. The 
hypomethylation (cg05575921) of AHRR has been suggested to be causally 
involved in lung cancer development [155].  
The GPR15 gene encodes for a cell membrane receptor that acts as a 
chemokine receptor for human immunodeficiency virus type 1 and 2. The 
altered gene expression and epigenetic regulation of GPR15 have been 











3 AIMS OF THE STUDY
The main purpose of this study was to be part of the path reducing the harmful 
consequences of tobacco dependence, at both the personal and the societal 
level. The study used a candidate gene perspective on CYP2D6, MAOA, MAOB, 
and SLC6A3 genes and utilized existing knowledge derived mainly from 
previous GWA -studies. The specific aims of this study were as follows: 
To increase knowledge about the mechanisms of nicotine addiction and 
to create new information especially concerning the role of methylation 
and the relation between genetic and epigenetic variation in the 
complicated process of smoking behaviour and nicotine addiction 
development.  
To combine the results of genetic and methylation studies by bringing 
new information in relation to several smoking-related phenotypes. We 
also aimed to advance the field of studies of associating individual 
differences in specific methylation pattern to smoking behaviour. 
To bring preliminary new data to support fresh solutions in the 
treatment of nicotine addiction. 
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4 MATERIALS AND METHODS
4.1 Study population
Our study population consisted of 1,230 Whites of Russian origin residing in 
the city of Saint Petersburg. The main characteristics of the study population 
are summarized in Table 5. Diverse background information was collected 
using comprehensive questionnaire, including FTND [125] and queries about 
several smoking-related phenotypes.  
Table 5. Characteristics of the study population
Mean (SD) / N 
(%)
Range




Never smoker 147 (12.6)
Non-smoker who has tried smoking without starting 
a habit
267 (22.9)
Current smokera 564 (48.3)
Former smokera,b 189 (16.2)
CPD
≤ 10 327 (40.4)
>10 482 (59.6)
Age at smoking initiation 18.7 (4.6) 6-49
Total duration of smoking (years)a 15.4 (11.4) 1-61
Age at smoking cessationa,b 36.3 (13.7) 16-75
Period of non-smoking after cessation (years)b 9.4 (9.5) 0.5-49
Withdrawal symptoms (yes) 145 (18.2)
Wish to quit (yes)a 373 (67.7)
FTND scores 2.6 (2.1) 0-10
aOnly subjects with minimum duration of smoking ≥ 1 year included
bOnly subjects with minimum time after smoking cessation ≥ 0.5 years 
included
CPD=cigarettes per day; FTND=Fagerström test for nicotine dependence
To improve the accuracy of the smoking status-related statistical 
evaluations, individuals with unclear smoking status, that is, smokers and 





smokers who had ceased smoking less than six months earlier were excluded 
from these analyses. 
This study was approved by the Ethics Committees of the N.N. Petrov 
Institute of Oncology and the Finnish Institute of Occupational Health. 
4.2 DNA extraction
DNA extracted manually from total white blood cells (WBCs) with the 
standard salt-chloroform method [162] and stored at -20°C, was used as the 
template in the genotyping analyses.
4.3 Selection of the genetic and epigenetic variations to 
be studied
The genes and their genetic and methylation variations were chosen in this 
study based on 1) the current knowledge of the relevance of the gene in the 
nicotine pathway, 2) the current knowledge of the effect of the gene variation 
to the protein, 3) the potential relevance to the gene function of the chosen 
methylation sites, with some variation discovered between individuals. The 
epigenetic perspective was added to this study by choosing short pieces of 
potentially relevant and highly polymorphic DNA methylation sites from each 
of the studied genes. 
4.4 Genotyping analysis
Several different genotyping methods were used in this study, determined by 
the quality and genetic location of polymorphisms. Table 6 lists all the studied 
genes, polymorphic sites, and the method used in their analysis. 
4.4.1 Polyacrylamide gel electrophoresis analysis
The VNTR polymorphisms studied from the MAOA and SLC6A3 genes were 
determined using the conventional polyacrylamide gel separation method for 
PCR amplification products. 
In the MAOA VNTR analysis, the PCR mixture included 0.5 U of hot-start 
Thermostar DNA polymerase (Syntol, Moscow), 1x PCR Buffer C (Syntol, 
Moscow), 2.5 mM MgCl2, 250 μM of each dNTP, 200 nM of each forward and 
reverse primers and water to the final volume of 10 μl. The PCR run consisted 
of an enzyme activation step (95ºС for 10 min), followed by 50 cycles of 95ºС 
for 20 s, 60ºС for 45 s, and 72ºС for 45 s. The sequences of the forward and 
reverse primers were TCCAGAAACATGAGCACAAAC and 
TGTAGGAGGTGTCGTCCAAG, respectively. After PCR, the amplification 
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products were separated in 10% acrylamide gel; the most common alleles, 3R 
and 4R, were identified by 223 bp and 253 bp amplification products, 
respectively. 
 
Table 6. The studied gene variations
Gene Description of the gene Variation Analyse method Refs
CYP2D6 cytochrome P450 family 2, 
subfamily D, member 6 
encodes one 
monooxygenase of the 
P450 superfamily, which is 
known to metabolize 25%













MAO-A monoamine oxidase A
encodes mitochondrial 
enzyme which catalyse 
the oxidative deamination 












MAO-B monoamine oxidase B 
encodes mitochondrial 
enzyme which catalyse 
the oxidative deamination 







SLC6A3 solute carrier family 6 
member 3, previously 









In Study IV, two VNTR polymorphisms in the SLC6A3 gene, the 40bp 
VNTR in the 3’non-coding region [163] and the 30bp VNTR located in intron 
8, were determined as follows. The 40bp VNTR was amplified in a PCR 
reaction containing 0.5 U of hot-start Thermostar DNA polymerase (Syntol, 
Moscow), 1x PCR Buffer for Taq polymerase, 2.5 mM MgCl2, 250 μM of each 
dNTP, 80 nM of each forward (5’-TCCTTGCGGTGTAGGGAAC-3’) and reverse 
(5’-TCAAGGCCAGGCAGAGTGT-3’) primers, and 3% DMSO. The final 
reaction volume was 10 μl. Amplification program consisted of enzyme 
activation step (95ºС for 10 min), followed by 47 cycles of 95ºС for 20 s, 63ºС 





separated in 10% acrylamide gel; the most common alleles, 9R and 10R, were 
identified by 424 bp and 464 bp amplification products, respectively.  
The primer sequences used for genotyping 30bp VNTR in intron 8 of 
SLC6A3 have been described in Guindalini et al. [116]. The PCR mixture 
consisted of 0.5 U of hot-start Thermostar DNA polymerase (Syntol, Moscow), 
1x PCR Buffer for Taq polymerase, 2.5 mM MgCl2, 250 μM of each dNTP, and 
200 nM each of the forward and reverse primers. The final reaction volume 
was 10 μl. The amplification program consisted of an enzyme activation step 
(95ºС for 10 min), followed by 40 cycles of 95ºС for 20 s, 65ºС for 45 s, and 
72ºС for 45 s. Again, after PCR, the amplification products were separated in 
10% acrylamide gel; the PCR fragment for the most frequent allele with 6 
repeats was 368 bp long. 
4.4.2 Allele-specific real-time PCR analysis
In the allele-specific analysis of MAOA rs1137070 in Study III, the PCR 
mixture contained 1 U hot-start Thermostar DNA polymerase (Syntol, 
Moscow) per 20 μl reaction, 1x PCR Buffer C (Syntol, Moscow), 2.5 mM MgCl2, 
175 μM of each dNTP, 180 nM each of the forward and reverse primers, and 1x 
SYBR Green I (Sigma-Aldrich). The PCR run consisted of an enzyme activation 
step (95ºС for 10 min), followed by 50 cycles of 95ºС for 15 s, 65ºС for 30 s, 
and 72ºС for 30 s. Melting curve analysis was performed to ensure specificity 
of PCR reaction. The sequences of the allele-specific forward primers were 
GGAAGGTGACCGAGAAAGAT and GGAAGGTGACCGAGAAAGAC, and the 
sequence of common reverse primer was GAGGCTAGAAGAAGGGAGAT. 
4.4.3 Taqman allelic discrimination analysis
In Studies II and III, the genetic variations CYP2D6*41 and MAOB rs1799836 
were detected with a TaqMan®-based method using the Applied Biosystems™ 
7500 Real-Time PCR system. 
Taqman Drug Metabolism Genotyping Assay C_34816116_20 was used 
to detect of the CYP2D6*41 allele. The PCR mixture for CYP2D6*41 detection 
consisted of 5μl 2x Roche Probe Master, 0.5μl Taqman Drug Metabolism 
Genotyping Assay, 20ng of DNA, and mQ-H20 to fill up 10μl total reaction 
volume. The PCR cycling conditions were 95°C for 10 minutes, 50 cycles of 
92°C for 15 seconds, and 60°C for 90 seconds. 
In the TaqMan allelic discrimination assay of MAOB rs1799836, the PCR 
mixture contained 1 U hot-start Thermostar DNA polymerase (Syntol, 
Moscow), 1x PCR Buffer C (Syntol, Moscow), 2.5 mM MgCl2, 250 μM of each 
dNTP, 180 nM of each forward and reverse primers, and 135 nM of each 
Taqman probe. A two-step PCR run was employed consisting of an enzyme 
activation step (95ºС for 10 min), followed by 50 cycles of 95ºС for 15 s and 
62ºС for 60 s. The sequences of primers and probes (supplied by Syntol, 
Moskow) were forward primer -TCCTTTAGGGAGCAGATTAG, reverse primer 
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- CAGGATCTGAAATGAAAGAAC, C-allele specific TaqMan probe - FAM-
CAAATAGCAAAAGCGACACCATCT-RTQ1, and T-allele specific TaqMan 
probe - R6G-CAAATAGCAAAAGTGACACCATCT-BHQ1. 
4.4.4 Taqman copy number analysis
Taqman copy number analysis was performed to discover deletions and 
duplications of CYP2D6. For this purpose, the Applied Biosystems™ 7500 
Real-Time PCR system was used with the Sequence Detection Software v1.4 to 
analyse the genotypes and to perform the real-time PCR for copy number 
analysis. The copy number results were interpreted with the CopyCaller® 
Software v2.0. 
Taqman Copy Number Assay Hs00010001_cn was used to detect of the 
CYP2D6*5 and *2XN alleles, together with Copy Number Reference Assay 
TERT by Applied Biosystems®. The PCR mixture for copy number detection 
consisted of 10μl 2x Genotyping Master Mix, 1μl 20x Copy Number Assay, 1μl 
20x Copy Number Reference Assay, 20ng DNA, and mQ-H20 to fill up 20μl 
total reaction volume. The PCR cycling conditions were 95°C for 10 minutes, 
40 cycles of 95°C for 15 seconds, and 60°C for 60 seconds. According to 
recommendations, four replications were made from each sample at the same 
run. 
4.4.5 Pyrosequencing analysis
The CYP2D6*2, *3, *4, *6, and *7 alleles were determined with 
pyrosequencing-based methods using a PSQ™96MA (PyroMark™Q96 ID) 
instrument, PSQ 96 SNP Software 1.1, and PyroMark Q96 accessories and 
reagents provided by Qiagen. The primary PCR was performed with forward 
and reversed primers, after which two separate nested PCRs were completed, 
amplifying two shorter fragments [164]. The CYP2D6*2, *3, and *7 alleles 
were sought from one of these PCR products by Multiplex Pyrosequencing 
[164]. The PCR mixture consisted of 5μl 10xBuffer (Roche), 0.2mM dNTP, 
1.5mM MgCl2, 0.24 μM primers A021 and A062 each, 1.5U Roche Fast Start 
Taq, 30ng of DNA and mQ-H2O to fill up 50μl total reaction volume. The PCR 
cycling conditions were 95°C for 5 minutes; 35 cycles of 95°C, 63°C, and 72°C 
each for 45 seconds; and a final extension of 72°C for 5 minutes. The annealing 
primer mix consisted of primers A145, A146, and A147 
(TTCAATGATGAGAACC for *2, CCTGCTCATGATCCT for *7, 
TGAGCTGCTAACTGA for *3, respectively) 0.16μl each, and annealing buffer 
(Qiagen) to reach total volume of 40μl per reaction. 
The CYP2D6*4 and *6 alleles were sought out from the other nested PCR 
product by Multiplex Pyrosequencing [164]. The PCR mixture consisted of 5μl 
10xBuffer (Roche), 0.2mM dNTP, 1.5mM MgCl2, 0.1μM primers A403 and 
A404 each, 1.5U Roche Fast Start Taq polymerase, 10ng of DNA, and mQ-H2O 





equivalent to the previous one. The annealing primer mixture consisted of 
primers A182 and A183 (CAAGAAGTCGCTGGAG for *6 and 
GCATCTCCCACCCCC for *4) 0.16μl each and annealing buffer (Qiagen) to 
reach total volume of 40μl per reaction. 
4.5 DNA methylation analysis
MAOA has two CpG islands covering part of the promotor region, intron 1 and 
exon 1. The methylation of these areas has been found to be functionally 
relevant and associated previously with substance-use disorders and mental 
disorders [137]. The other two studied methylation sites, located in MAOB and 
SLC6A3, were chosen based on the potential relevance on gene expression and 
some associations previously relating the methylation levels of the genes to 
mental disorders and alcoholism. As far as we know, the methylation of 
CYP2D6 has not been previously studied in these contexts. However, we 
introduced this aspect into our study because of the crucial importance of the 
CYP2D6 genotype in determining an individual’s drug response. The studied 
methylation sites are presented in detail in Table 7. 
For the methylation analysis, the DNA was treated with bisulfite to 
convert unmethylated cytosines into uracils while leaving methylated 
cytosines unchanged. For this purpose, the EpiTect Fast 96 DNA Bisulfite Kit 
provided by Qiagen was used for samples of 2μg DNA, or, in case the 
availability of DNA was limited, 500ng of DNA. The protocol was obeyed 
according to manufacturer recommendations. 
All methylation analyses were performed by pyrosequencing using the 
PSQ™96MA instrument and using accessories and reagents provided by 
Qiagen. For this purpose, we chose ready-made assays that consisted of two 
PCR primers and one sequencing primer. The results were interpreted with 
PSQ 96 SNP Software 1.1 or PyroMark Q96 ID App Software 2.5. 
 
Table 7. The studied DNA methylation sites
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For the methylation analyses on the CGI of CYP2D6, we chose to use a 
ready-made assay (Hs_CYP2D6_02_PM PyroMark CpG Assay). The 
PyroMark PCR Kit was used to prepare a PCR mixture consisting of 12.5μl PCR 
Master Mix, 2.5μl Coral loading dye, 5μl Q-solution, 3μl PCR primer set, and 
3μl DNA sample. The PCR cycling conditions were 95°C for 15 minutes; 45 
cycles of 94°C, 56°C, and 72°C each for 30 seconds; and a final extension of 
72°C for 10 minutes. The pyrosequencing procedure followed the Qiagen 
protocol. The sequence to analyse was CGG TGT CGA AGT GGG GGG CGG 
GGA CCG C and, after bisulfite treatment, YGG TGT YGA AGT GGG GGG YGG 
GGA TYG T. The Y indicates the potentially methylated cytosines. 
The methylation analyses of the MAO genes were carried out using ready-
made assays for both the loci of interest (Hs_MAOA_04 and Hs_MAOB_02). 
PyroMark PCR Kit was used for each MAO methylation study separately to 
prepare a PCR mixture consisting of 12.5 μl PCR Master Mix, 2.5 μl Coral 
loading dye, 5 μl Q-solution, 3 μl PCR primer set (Hs_MAOA_04 or 
Hs_MAOB_02), and a 3 μl DNA sample for MAOA and a 2 μl DNA sample for 
MAOB, respectively. The PCR cycling conditions were 95°C for 15 minutes; 45 
cycles of 94°C, 56°C, and 72°C each for 30 seconds; and a final extension of 
72°C for 10 minutes.  
The pyrosequencing procedure followed the protocol by Qiagen. For the 
MAOA gene, the gene sequence to be analysed was CGC TGG GCG CTG GGG 
GCG GTG TTC TGC TTC CCG C before bisulfite treatment and YGT TGG GYG 
TTG GGG GYG GTG TTT TGT TTT TYG T (the Y indicates the potentially 
methylated cytosines) after the treatment. For the MAOB gene, the sequence 
to be analysed was CGG CGC TCT GGA CCC ACT AGA GCC CTG CCC GTG 
CGT before bisulfite treatment and YGG YGT TTT GGA TTT ATT AGA GTT 
TTG TTY GTG YGT after the treatment. 
A PyroMark PCR Kit was used for SLC6A3 methylation study to prepare 
PCR mixture consisting of 12.5 μl PCR Master Mix, 2.5 μl Coral loading dye, 5 
μl Q-solution, 3 μl PCR primer set (Hs_SLC6A3_01), and 2 μl bisulfite-
converted DNA sample. The PCR cycling conditions were 95°C for 15 minutes; 
45 cycles of 94°C, 56°C, and 72°C each for 30 seconds; and a final extension of 
72°C for 10 minutes.  
The pyrosequencing procedure followed the protocol by Qiagen. For the 
SLC6A3 gene, the gene sequence to be analysed was GCG GCG GCG GCT TGC 
CRG AGA CTC GCG AGC TCC GC before bisulfite treatment and GYG GYG 
GYG GTT TGT TRG AGA TTY GYG AGT TTY GT (the Y indicates the 
potentially methylated cytosines) after the treatment. 
4.6 Quality control
For quality control, 15% of the genotype results achieved with pyrosequencing, 
and at least 5% of results achieved with other genotyping methods were 





detected with pyrosequencing re-analysis, whereas no discrepancies were 
observed with other methods used, except with the accuracy in detection of 
four or more copy numbers, the results of which were interpreted as *2XN. 
No notable difference with 10% replications of CpGs in CYP2D6, MAOB, 
and SLC6A3 or with 5% replications of CpGs in MAOA in pairwise 
comparisons were found in the methylation analyses. 
4.7 Statistical analysis
Several smoking-related phenotypes, that is, smoking status, duration of 
smoking, intention to quit, duration of non-smoking period after cessation, 
withdrawal symptoms, CPD, and FTND score (described earlier, in Table 5) 
were explored in the statistical analyses. 
All the statistical analyses were conducted with IBM SPSS Statistics 
versions 20, 23, or 24 (SPSS Inc., Chicago, IL) in Studies II, III, and IV, 
respectively. Either binary logistic regression or multinomial logistic models 
were used. Logistic regression analyses were used in both genotype and DNA 
methylation analyses when studying associations with the above-listed 
smoking-related phenotypes. Binary classifications were applied with the 
analysed phenotypes. A multinomial logistic model, on the other hand, was 
used in the analyses studying the effect of gender, age, and genotypes on 
CYP2D6 and SLC6A3 methylation levels. Both the crude odds ratios (ORs) and 
the ORs adjusted for age were calculated in each analysis. Based on the age 
range, the participants were categorized into three age groups: 18–27 years 
old, 28–47 years old, and over 47 years old. 
There were special features applying each studied genetic and epigenetic 
polymorphism, which are introduced below with their implications to 
statistical evaluations. 
CYP2D6 
The CYP2D6 phenotypes of the study subjects were interpreted from their 
CYP2D6 genotypes based on the current knowledge (www.cypalleles.ki.se) of 
the functional consequences of the CYP2D6 alleles (Figure 5).  
Although the methylation percentages of the four CpG sites in CYP2D6 
gene were contemplated separately in the methylation analyses, for further 
analyses only a mean methylation value of the four sites was decided to be used 
in presenting the results since it best describes the methylation of CYP2D6 
locus and did not notably differ between the single CpG sites. Consequently, 
the mean CYP2D6 methylation was categorized into three classes representing 
low, intermediate, and high methylation values specific to the area under 
study. Based on the deviation of mean methylation values in the study 
population, a methylation degree of less than 51% was considered low, 51–70% 
intermediate, and over 70% high. To gain sufficient power, the analyses on the 
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relationship between the CYP2D6 alleles and methylation levels were only 
conducted with the high frequency alleles (minor allele frequency over 0.02). 
MAOs 
All the statistical analyses of MAO genes were performed separately for males 
and females; the MAO genes are located in X-chromosome, and therefore men 
have only one copy of each gene, whereas women have two copies. Due to the 
hemimethylation of MAO genes resulting from their location on the X-
chromosome, the methylation of these genes also differs significantly between 
the sexes.  
Since the MAOA VNTR polymorphism analyses revealed remarkable 
variation in the number of repeats in our study population, we grouped the 
alleles based on existing knowledge about their relation to gene function to 
gain sufficient group sizes for meaningful statistical analyses. Consequently, 
female carriers of any two of the long alleles (3.5R, 4R, or 5R), expected to 
result in more active enzymes [165, 166], were categorized as referents, to 
whom individuals with one of the mentioned long alleles together with a short 
allele (3R or 2R) were compared to. Furthermore, the third group consisted of 
individuals with two copies of short alleles. Since the prevalence of the rare 2R 
variant was very low in our study population, it could not be analysed 
separately, and it was therefore analysed together with 3R; both of these forms 
result in lower transcriptional activity.  
For men, the MAOA VNTR alleles were grouped in the same way as for 
women, except that only two groups were formed, that is, carriers of the long 
or short alleles. 
For the studied gene polymorphisms, that is, MAOA 1460 and MAOB 
int13, the x2 analysis with a cut-off p-value of 0.05 was used to test for a 
deviation from Hardy–Weinberg equilibrium (HWE). 
Although four CpG sites in the MAOA gene were determined separately, 
only the mean methylation value of the four sites was used in the further 
analyses, the mean value best describes the methylation of the MAOA locus in 
women, as the methylation percentages did not notably differ between single 
CpG sites and were fairly low in general.  
Since the MAOA methylation values in men were extremely low, they 
could not be included in the statistical analyses. In women, the mean MAOA 
methylation levels were categorized into three classes, representing decreased, 
mean, and increased methylation; this categorization was made separately for 
each studied gene area. On basis of the deviation of mean methylation values 
in the study population, a methylation degree below 9% was considered as 
decreased, 9–11% as mean, and over 12% as increased. 
The four CpG sites in the MAOB gene were determined separately because 
they exhibited large differences in their methylation levels. The methylation 
values in each CpG site in the MAOB gene were also categorized into three 





methylation according to the distribution of the methylation in each spot. 
These classifications are discussed in more detail in the Results -section. 
SLC6A3 
Study IV had an 80% power to detect odds ratios (ORs) from 1.52 to 1.93, 
depending on the frequency of the VNTR allele to be studied and the size of 
the investigated subpopulation (range 560–1,230) The calculations of a two-
sided alpha of 0.05 were performed using standard methods. 
The two studied SLC6A3 VNTR polymorphisms were present diversely in 
our study population. The carriers of two of the most frequent variations (6R 
for the 30bp VNTR and 10R for the 40bp VNTR) were selected as a referent 
group that was compared to the individuals carrying one copy of the other 
frequently observed variation (5R for the 30bp VNTR and 9R for the 40bp 
VNTR) [114]. The individuals carrying two copies of rare variants were 
excluded from the statistical analyses since their low frequency did not allow 
their meaningful inclusion in these assessments. 
Although the methylation values of six CpG sites in the SLC6A3 gene were 
determined separately, only five of them were analysed due to the very low 
overall methylation values of one of the sites. When significant differences 
were observed between adjacent CpG sites or mean methylation values, both 
single and mean methylation values of these five sites were analysed and 
reported separately. 
The SLC6A3 methylation levels were categorized into three classes 
representing decreased, mean, and increased methylation, respectively. This 
categorization was done separately for each studied CpG site as well as for the 
mean methylation value according to the distribution of the methylation level 






5.1 Genetic and epigenetic variations in CYP2D6 gene 
and smoking phenotypes (II)
5.1.1 Association of genetic variations of CYP2D6 with smoking 
phenotypes
The frequencies of the CYP2D6 variant alleles in the study population were 
0.357, 0.013, 0.177, 0.016, 0.010, 0.0004, and 0.076 for *2, *3, *4, *5, *6, *7, 
and *41, respectively. Based on the genotype data, the study population was 
comprised of 89.3% EMs (extensive metabolizer), 6.0% PMs (poor 
metabolizer), and 4.7% UMs (ultrarapid metabolizer; Figure 5). The UM 
phenotype refers to duplication of the CYP2D6 gene (*2XN).  











Figure 5 The interpreted relationship of the CYP2D6 genotype to the CYP2D6 phenotype
A significant association was found between the CYP2D6 genotype and 
cigarette consumption; the interpreted CYP2D6 UM phenotype posed higher 
odds of becoming a heavy smoker (consuming over 10 cigarettes per day) 
compared to PM (OR 3.36, 95% CI 1.24–9.16; Table 8). Although a similar 
tendency was seen in comparison to the interpreted EM phenotype (OR 1.82, 
95% CI 0.95–3.50), the association failed to reach statistical significance. No 
association was found between the smoking status nor other measured 








5.1.2 Association of epigenetic variations in CYP2D6 gene with
smoking phenotypes
5.1.2.1 Effect of background variables in the gene methylation levels
The methylation values obeyed a normal curve (Figure 6). Based on these 
results, the methylation values were categorized into three groups; two lowest 
classes compose the group of low methylation (less than 51%), the two most 
prevalent classes the group of intermediate methylation (51–70%), and the 
two highest classes the group of high methylation (over 70%).  
Group Methylation Frequency Percent
1 ≤40% 84 6.9
2 41-50% 192 15.8
3 51-60% 350 28.9
4 61-70% 342 28.2
5 71-80% 198 16.3
6 ≥81% 47 3.9





Since no significant differences were observed between the studied four 
adjacent CpG sites in relation to different phenotypes, only the mean 
methylation values were considered in the further statistical analyses. 
Gender-related differences in the methylation levels were observed for 
the CpG sites; while the overall mean methylation values among males and 
females were very similar (60.5% and 58.5%, respectively), males were more 
likely (OR 1.63, 95% CI 1.14–2.32) to have the higher (over 70%) methylation 
status than the lower methylation status (less than 51%) compared to women 
(Table 9).  
Age was also found to influence the mean methylation values of CYP2D6. 
The effect was seen irrespective of the smoker status (smoker/non-smoker). 
When the extreme age groups were compared, the methylation levels were 
found to accumulate with age; the odds for higher (over 70%) methylation 
levels was nearly 3-fold in the latter age group (OR 2.74, 95% CI 1.73–4.34; 
Table 9). 
5.1.2.2 Association of the gene methylation levels with smoking 
phenotypes
We found no associations between most of the measured smoking-related 
phenotypes and CYP2D6 methylation status. However, among subjects for 
whom data was available about smoked cigarettes per day, higher methylation 
levels (over 70%) were found to be inversely related (OR 0.56, 95% CI 0.35–
0.91) to heavier smoking (over 10 cigarettes per day) when adjusted for gender 
and age (Table 10). When only current smokers were considered, the results 
remained unchanged. 
5.1.3 Associations between genetic variations and gene methylation 
levels
Significant associations were found between mean CYP2D6 methylation levels 
and the CYP2D6 high-frequency alleles. In multinomial logistic analyses, 
adjusted for gender and age, a significant effect on the odds of high 
methylation degree was seen for the CYP2D6*4 allele (OR 2.37, 95% CI 1.62–
3.47), and the reverse for the *41 allele (OR 0.27, 95% CI 0.15–0.47) and the 
*2/*2 genotype (OR 0.03, 95% CI 0.02–0.07; Table 11). Additionally, the 
interpreted CYP2D6 PM phenotype was more frequently associated with high 
















5.2 Genetic and epigenetic variations in dopamine 
pathway genes and smoking phenotypes (III and IV)
5.2.1 Association of variations of dopamine pathway genes with 
smoking phenotypes
The prevalence of the MAOA 1460 and MAOB int13 variant alleles in our study 
population was 0.353 and 0.425, respectively, for women and 0.345 and 
0.430, respectively, for men, which is in good agreement with the prevalence 
reported previously for the general Finnish population (0.356 and 0.463); they 
also closely matched the overall prevalence reported for Europeans (0.311 and 
0.453; https://www.ncbi.nlm.nih.gov/snp/). Moreover, these polymorphisms 
were found to be in HWE in women, whereas HWE could not be calculated in 
men because the MAO genes are located on the X-chromosome, resulting in 
men having only one copy of these genes. 
All the known MAOA VNTR variants were represented in our study 
population. In women, the prevalence of carriers of two long alleles (3.5R4R, 
4R4R, or 4R5R), of one short and one long allele (3R4R, 3R5R, 3R3.5R, or 
2R4R), and of two short alleles (2R3R or 3R3R) were 0.361, 0.494, and 0.145, 
respectively. In men, the prevalence of carriers of the long and short alleles 
were 0.620 and 0.380, respectively. 
The prevalence of the common SLC6A3 VNTR variants of 40bp length, 
ranging from 3 to 12 repeats in the general populations [63, 163], was 0.598 
for 10R10R, 0.333 for 9R10R, 0.052 for 9R9R, and 0.017 for either 9R or 10R 
having one of the rare variants (6R, 7R, 8R, or 11R). Additionally, the 
prevalence of the VNTR variants of 30bp length was 0.643 for 6R6R, 0.312 for 
5R6R, and 0.042 for 5R5R. In addition, few very rare variants (data not 
shown) were present in 0.2% of our study population. 
In females, the homozygotes for MAOA 1460 variant allele were at lower 
risk of becoming smokers. The association was found both when current 
smokers were compared to non-smokers (OR 0.44, 95% CI 0.21–0.91) and 
when a combined group of current or former smokers was compared to non-
smokers (OR 0.48, 95% CI 0.25–0.95). Moreover, the carriers of the 
homozygous genotype of the MAOB int13 variant allele were at higher risk of 
becoming smokers; the OR was 2.16 (95% CI 1.08–4.33) for current smokers 
and 2.17 (95% CI 1.11–4.22) for the group of current or former smokers (Table 
12). In males, these genotypes were not associated with smoking status. 
The heterozygous MAOA VNTR short allele genotype was associated with 
a lower risk of starting smoking compared to homozygous genotype for the 
long alleles (OR 0.53, 95% CI 0.32–0.88). Carriage of homozygous genotype 
for the short alleles posed a similar risk for smoking initiation (OR 0.49, 95% 











When individuals with any smoking history were compared to never smokers, 
the carriers of 9R variants of SLC6A3 40bp VNTR were at lower risk of starting 
smoking compared to carriers of 10R10R genotype (OR 0.62, 95% CI 0.43–0.88; 
Table 13). Similar associations were found when the carriers of 5R variants of 30bp 
VNTR were compared to the carriers of 6R6R genotype (OR 0.53, 95% CI 0.37–
0.75). 
Additionally, several associations were found between the 40bp VNTR 
polymorphism and the likelihood of starting to smoke and develop nicotine 
addiction (Table 13). First, the carriers of 9R variant were at higher risk of becoming 
either smokers or ex-smokers compared to non-smokers who did not continue the 
habit after the initial experimenting with smoking cigarettes (OR 1.44, 95% CI 1.06–
1.94). This variant allele was also associated with increased risk for developing 
nicotine addiction and with higher FTND scores (OR 1.65, 95% CI 1.04–2.60). 
Moreover, the 9R variant genotypes posed a lower risk of continued tobacco 
consumption, which was observed both when either current smokers (OR 0.66, 95% 
0.46–0.94) or only those aiming to quit smoking were compared to those who had 
succeeded in smoking cessation (OR 0.59, 95% CI 0.40–0.88). 
No significant associations were observed between the MAO or SLC6A3 








5.2.2 Association of epigenetic variations in dopamine pathway genes 
with smoking phenotypes
5.2.2.1 Effect of background variables in the gene methylation levels
The methylation values of MAOA, MAOB, and SLC6A3 were defined as 
decreased, mean, or increased, respectively, according to the distribution of 
the methylation in each site so that each group included approximately one 
third of the study population. The frequencies and definitions of methylation 
levels are listed in Table 14. 
The MAOA gene appeared to be methylated to a very limited extent; the 
mean methylation level was 10.4% in women and 0.5% in men. Because of the 
almost negligible methylation level in men, they were excluded from the 
further MAOA methylation level analyses. 
In the MAOB gene, the methylation levels showed significant variation 
between adjacent CpG sites. The differences in methylation between sexes was 
also notable: The mean methylation levels in women were 62.4% for MAOB_1, 
59.8% for MAOB_2, 36.1% for MAOB_3, and 40.4% for MAOB_4 sites. In 
men, the respective methylation levels were 41.3%, 69.3%, 24.4%, and 34.1%. 
In the SLC6A3 gene the mean methylation values of the six adjacent CpG 
sites were, in their numerical order, 8.83%, 6.98%, 9.84%, 19.21%, 2.26%, and 
9.43%. The CpG site SLC6A3_5 was excluded from further analyses due to 
very low overall methylation values. Furthermore, in addition to the 
methylation values of single CpG sites, the mean values of the remaining five 
CpG sites (SLC6A3_1, SLC6A3_2, SLC6A3_3, SLC6A3_4, SLC6A3_6), were 
included in the analyses. 
The SLC6A3 methylation levels appeared to be strongly related to both 
age and gender (Table 15); subjects over 47 years old were remarkably more 
likely to have increased mean methylation levels than those under 28 years old 
(OR 18.38, 95% CI 11.45–29.51), and males were 1.5 times more likely to 






Table 14. Distribution of the methylation levels of the MAO and SLC6A3 genes in
the study populationa






MAOA 0–8% decreased 162 31.3
9–11% mean 180 34.7
12–41% increased 176 34.0
MAOB_1 34–60% decreased 170 32.8
61–64% mean 187 36.0
65–75% increased 162 31.2
MAOB_2 40–56% decreased 143 27.6
57–61% mean 195 37.6
62–84% increased 181 34.9
Men
MAOB_4 14–32% decreased 235 33.5
33–35% mean 225 32.1
36–54% increased 241 34.4





SLC6A3_mean 1–9% decreased 367 30.3
10–11% mean 417 34.4
12–23% increased 429 35.4
SLC6A3_1 0–7% decreased 370 30.4
8–9% mean 428 35.1
10–20% increased 421 34.5
SLC6A3_2 0–5% decreased 143 22.8
6–7% mean 195 39.8
8–31% increased 181 37.6
SLC6A3_3 0–8% decreased 398 32.6
9–10% mean 385 31.6
11–34% increased 436 35.8
SLC6A3_4 0–16% decreased 354 29.2
17–20% mean 438 36.1
21–38% increased 421 34.7
SLC6A3_6 0–8% decreased 392 32.3
9–10% mean 464 38.3
11–36% increased 357 29.4
aOnly results on the methylation sites presented in the results section are shown
bThe methylation levels were grouped according to the distribution of the methylation in 








5.2.2.2 Association of the gene methylation levels with smoking 
phenotypes
Only the mean methylation level of MAOA and the specific sites of MAOB_1 
and MAOB_2 in women, and the MAOB_4 site in men were significantly 
associated with one or more smoking-related phenotypes. Therefore, only 
results related to these CpG sites are presented below.  
The increased methylation levels of the MAOA gene in women was found 
to be related to smoking background; female smokers (either current or 
former) were less likely to have increased methylation compared to non-
smokers (OR 0.59, 95% CI 0.38–0.92). Moreover, the current smokers had 
increased methylation of the MAOA gene more often than the former smokers 
(OR 2.33, 95% CI 1.07–5.07; Tables 16 and 17). 
In women, the increased methylation of two CpG sites of the MAOB gene, 
MAOB_1 and MAOB_2, was associated with smoking history; the current 
female smokers had higher methylation values in the MAOB_1 more often 
than former smokers (OR 2.57, 95% CI 1.20–5.51; Tables 16 and 17). Moreover, 
current smokers who wanted to quit smoking were more likely to have 
increased methylation both in MAOB_1 (OR 2.37, 95% CI 1.05–5.35), and 
MAOB_2 sites (OR 2.72, 95% CI 1.17–6.34) than ex-smokers. The increased 
methylation of MAOB_2 was inversely related to women with any history of 
smoking when compared to never smokers (OR 0.32, 95% CI 0.1–-0.61). This 
relation was also observed when comparing smokers (either current or 
former) to non-smokers (OR 0.55, 95% CI 0.35–0.87; Tables 16 and 17). 
In men, by contrast, the increased methylation of MAOB_4 was more 
often observed in current smokers than in non-smokers (OR 1.63, 95% CI 
1.05–2.55) or former smokers (OR 1.81, 95% CI 1.04–3.14; Tables 16 and 17). 
Our study revealed no relations between MAO methylation levels and the 
studied smoking-related phenotypes other than smoking status. Moreover, 
our study could not replicate the previous findings relating the methylation of 
MAOA gene to FTND [145]. 
Because the results were very similar for adjacent CpG sites regarding 
methylation levels of studied CpG sites and smoking status, the following 
results are from analyses focused on examining the SLC6A3 mean methylation 
value calculated from the five single CpG sites.  
First, we found that the current smokers had higher odds of having 
increased mean SLC6A3 methylation levels than the former smokers; this was 
seen both when all current smokers were considered together (OR 2.72, 95% 
CI 1.63–4.53) and when smokers wishing to quit were studied separately (OR 
2.44, 95% CI 1.40–4.24). In addition, an association to increased methylation 
was observed when smokers were compared to non-smokers and ex-smokers 
grouped together (OR 1.40, 95% CI 1.01–1.94). Moreover, lower odds of having 
increased mean methylation levels were observed when former smokers were 




associations were observable only when age and gender were taken into 
account in the statistical analyses (Table 18). No other associations were 
discovered between the SLC6A3 methylation levels and the smoking-related 
phenotypes. 
5.2.3 Associations between genetic variations and gene methylation 
levels
No significant associations were observed between the MAO methylation 


















In the past few years, the number of smoking-related methylation studies has 
increased rapidly. While these studies have succeeded in linking gene-specific 
methylations to smoking, they have not revealed whether these methylation 
patterns are caused by smoking or whether the genetic factors have actually 
affected the methylation patterns and thus influenced smoking behaviour. 
We undertook a candidate gene approach from a genetic and epigenetic 
point of view to explore the potential interactions between genetic 
polymorphisms and DNA methylation and various smoking behaviour 
phenotypes. We aimed both to verify previous findings on the association of 
genetic polymorphisms with nicotine dependence and to generate new 
knowledge for this important area of research. 
In particular, our study provides new insights into the methylation of the 
CYP2D6, MAOA, MAOB, and SLC6A3 genes, which have previously been 
linked to some extent with psychiatric disorders and mental health conditions, 
by now associating them also with smoking behaviour phenotypes. This led us 
to suggest that 1) genetic and epigenetic profile of CYP2D6 has effects on 
smoking quantity and 2) genetic and epigenetic profile modifying the 
availability of dopamine shapes the risk of nicotine addiction. 
6.1 The effect of age and gender on DNA methylation
profiles
Age has been shown to impact human CYP2D6 expression, especially in 
brains. At birth, the CYP2D6 enzyme levels are low in the brain but 
subsequently increase gradually, being highest after the age of 65. Instead, the 
hepatic CYP2D6 has been suggested to rapidly reach an age-independent 
steady-state level [167].  
We found an evident contribution of age to the CYP2D6 methylation 
levels in blood cells; the CYP2D6 methylation levels increased with age, which 
may lead to lower availability of CYP2D6 in the blood cells at a higher age. This 
suggests that age has an impact on CYP2D6 expression in circulating blood 
cells by affecting methylation mechanisms. Alternatively, this could represent 
an increasing effect of elevated methylation in gene bodies on gene expression. 
Thus, methylation could affect CYP2D6 enzyme activity, which may lead to 
crucial differences in the dose response to CYP2D6 metabolized drugs due to 
altered functional capacity later in life. 
In Study IV, subjects over 47 years old were 18 times more likely to have 
increased mean methylation levels in the first intron of SLC6A3 than subjects 
under 28 years old, which links higher DNA methylation values in this locus 





SLC6A3 promoter methylation and age [142]. Thus, the pattern of DNA 
methylation in the SLC6A3 gene at least seems to vary remarkably between 
different gene areas. Nevertheless, our results are in line with an observed 
increase in the general methylation values with age [168].  
Despite contradictory findings regarding gender-related differences in 
DNA methylation among specific CpG sites, men tend to have higher overall 
methylation values in autosomes [168]. This also applies to the findings on the 
CYP2D6 and SLC6A3 genes in Studies II and IV. However, in our study, the 
gender-related difference in CYP2D6 and SLC6A3 methylation levels was only 
a few percent, which is anticipated to be a rather irrelevant difference from the 
gene expression point of view. Yet, in both cases, men were found to have the 
same 1.5-fold odds of high methylation values compared to women. 
Since MAO genes are expressed in the X-chromosomes, there are some 
obvious differences between genders, as there is only a single copy of these 
genes in males, in contrast to the autosomal genes. In general, women have 
much higher DNA methylation on the X chromosome, partly due to X-
inactivation (silencing of one of the two X chromosomes), which is also true 
for the MAO genes in Study III.  
We found almost negligible methylation levels among males in the 
studied area of MAOA, and in all but one of the CpGs studied in MAOB, lower 
methylation values were observed among males compared to females. 
Therefore, gender appeared to have an opposite effect on methylation of the 
MAO genes than on the methylation of the studied autosomal genes, except 
for one specific site in MAOB, which emphasizes the existence of individual 
deviant CpGs. 
6.2 Genetic and epigenetic variations in CYP2D6 gene 
and smoking phenotypes (II)
Study II introduces novel information about the methylation status of CYP2D6 
and its connection to gender, age, and genotype, and links the CYP2D6 
genotype and its methylation status to smoking quantity. 
In our previous study on Finnish cancer patients and healthy controls, 
we found an association between smoking habits and functional CYP2D6 gene 
variations. A significant over-representation of the UM phenotype related 
CYP2D6 genotypes was found in smokers, with a two-fold increase in heavy 
smokers compared to occasional smokers (OR 2.3, 95% CI 1.2–4.4) and a four-
fold increase in heavy compared to never smokers (OR 4.2, 95% CI 1.8–9.8) 
[33]. The present results support the previous findings, although the genotype 
effects on cigarette consumption were mainly seen in the comparisons of 
extreme groups: Smokers with the interpreted UM phenotype were more likely 
to be heavy smokers than smokers with the interpreted PM phenotype. 




related genotypes being associated with increased risk of heavy smoking and 
for decreased metabolism being related to light smoking.  
In recent years, large GWA studies have identified multiple other genetic 
loci associated with smoking behaviour, but not CYP2D6. The plausible reason 
for this is that the CYP2D6 gene is poorly covered in these studies, for example, 
in the recent GWAS meta-analysis on genetic factors in smoking behaviour 
[74]. 
As for the epigenetic analyses, although smoking alters global 
methylation status, we decided to focus on specific loci in seeking CYP2D6 
methylation patterns linked to a smoking-related phenotype. Such a link was 
indeed found between cigarette consumption and methylation status; the low 
CYP2D6 methylation status was linked to heavy smoking. Moreover, the 
methylation levels in the studied CYP2D6 loci appeared to be strongly 
genotype-dependent, establishing a strong linkage between the alleles and 
methylation level.  
The observed associations of CYP2D6*41 and *2 alleles with low 
methylation levels could result from methylation disturbing differences in 
DNA sequence. This is in agreement with the proposed significant role of 
genetics on inter-individual variability in DNA methylation, suggesting the 
existence of some locally impacting allele-specific DNA methylation (ASM), in 
which a CpG located in a SNP site is methylated only when a C nucleotide 
exists (CpG-SNP), spread to neighbouring CpGs. In support of this view, the 
ASM has previously been observed to occur in other CYP genes, more 
specifically in the CYP2A6-CYP2A7 gene cluster [169].  
The observed association between methylation and genotype, in turn, 
supports the idea that besides being the consequence, methylation could, in 
fact, have a causal impact on smoking. It is thus possible that the low 
methylation status of the CYP2D6 gene leads to a higher risk of the individual 
becoming heavy smoker. The methylation status should therefore be 
considered an important factor in smoking phenotypes. 
When the associations between the interpreted CYP2D6 phenotypes and 
methylation levels were studied, the poor-metabolism-associated genotypes 
were more prevalent among subjects with high CYP2D6 methylation levels, 
whereas the extensive-metabolism-associated genotypes were linked to low 
CYP2D6 methylation levels. As stated above, the low CYP2D6 methylation 
status was associated with high cigarette consumption and the high CYP2D6 
methylation values with low cigarette consumption. The genotype and 
methylation data therefore consolidate each other and suggest that the low 
CYP2D6 methylation status increases the CYP2D6 metabolism capacity, 
similarly to the UM phenotype, and could therefore enhance the need for 
frequent smoking to maintain sufficiently high blood nicotine levels. 
Consequently, the effect of CYP2D6 phenotype on smoking heaviness could be 






Since CYP2D6 is an important metabolizer of several drugs, it can be 
speculated to also have a role in nicotine metabolism. However, as nicotine is 
primarily metabolized to cotinine by CYP2A6, it may well be that CYP2D6 only 
has a minor contribution in this context. Nonetheless, our study linking the 
genetic and epigenetic profile of CYP2D6 only to cigarette consumption, and 
not to any of the other studied smoking phenotypes, supports the idea of 
CYP2D6 having a role also in the nicotine metabolism. 
There is also evidence of an alternative route for CYP2D6 variations to 
affect individual’s smoking behaviour. Since CYP2D6 can convert tyramine to 
dopamine, polymorphisms in the CYP2D6 gene can cause individual variation 
in the levels of these amines in the brain, thereby affecting personality and 
behaviour [170, 171]. In agreement with this, CYP2D6 genotypes have been 
associated with differences in serotonin and dopamine levels that have been 
linked with certain characteristics [172, 173]. These personality-related traits 
could thus increase both the person’s risk of starting to smoke and of becoming 
addicted to smoking. Our study, however, failed to provide support for the 
influence of this alternative route on individual smoking behaviour. 
6.3 Genetic and epigenetic variations in dopamine 
pathway genes and smoking phenotypes (III & IV)
Studies III and IV focused on exploring smoking-behaviour-related 
associations with three genes that have been strongly associated with 
dopamine availability, namely, MAOA, MAOB, and SLC6A3. Our results, both 
supporting some previous findings and providing some novel insights into 
genetic and epigenetic factors in smoking behaviour, prompted us to suggest 
that both the MAO and the SLC6A3 genes shape the risk of smoking 
dependence by affecting smoking behaviour, especially relating them to 
phenotypes of smoking initiation and cessation.  
The connections discovered in Study III between smoking behaviour and 
genetic or epigenetic variation of the MAOA gene support the previous 
findings in the field, indicating the relevance of MAOA to several aspects of 
behaviour [67, 68, 120-122, 134, 145, 146]. Female smokers demonstrated a 
halved likelihood of having the MAOA 1460 variant alleles or one or two copies 
of the VNTR short alleles compared to non-smokers. In addition, the current 
female smokers had significantly higher odds of having increased methylation 
of the MAOA gene than ex-smokers, whereas an inverse relation was observed 
when current and former smokers were compared to non-smokers. Since the 
short VNTR alleles, 2R and 3R, are denoted as low-activity alleles, and since 
high methylation of the gene promoter area is generally considered to be 
associated with lower enzyme activity, these findings support each other and 
indicate higher dopamine levels among female smokers, thereby placing them 




The observations of both smoking and quitting smoking being associated 
with diminished methylation in the MAOA gene are of particular interest. 
These abnormalities in DNA methylation may indicate the importance of a 
single CpG site to the smoking phenotype that could not be analysed separately 
in our study due to the low overall methylation values in MAOA. This view is 
also supported by findings related to other mental health conditions [134].  
Intriguingly, based on several studies on MAOA methylation and mental 
disorders, an opposite trend can be seen between genders. Among women, 
decreased MAOA methylation is associated with certain types of mental 
disorders, such as anxiety and affective disorders, while among males it is 
often the hypermethylation of the MAOA that has been associated with other 
types of mental disorders, that is PTSD, antisocial personality disorder, 
conduct disorder, and borderline personality disorder [137]. In our study (III), 
the discovered associations between smoking and diminished MAOA 
methylation in women resembled this trend seen in studies of mental illnesses. 
Our inability to replicate the findings relating the methylation of the 
MAOA gene to FTND [145] may be due to the low overall methylation levels of 
MAOA obtained with the methods used in our study, or due to the fairly low 
overall FTND values of the study population. 
As for the observed associations between the MAOB gene and smoking 
status, very different associations were discovered between sexes, both in the 
genotype and in the methylation level analyses. In men, only the increased 
methylation of the MAOB_4 site was associated with current smoking 
compared to former smoking or not smoking. Since no association was found 
with MAOB polymorphism, this relation could be explained by the fact that 
smoking increases methylation on this specific site. Since smoking has overall 
been shown to decrease global methylation, the increase in this methylation 
site could be an example of gene-specific methylation alteration caused by 
smoking. 
The MAOB-related findings in women were much more complicated in 
nature than those in men. First, as a novel finding, we found that the rare 
MAOB int13 allele, associated with lower MAO-B activity [174], increases 
women’s risk of starting to smoke: The probability of having been current 
smoker or either current or former smoker was more than twice as high as 
having never started consuming cigarettes.  
The increased methylation of one specific CpG site (MAOB_1) was also 
more common among current female smokers and among those who wished 
to quit compared to former smokers. A similar association was found between 
the MAOB_2 site and the ability to quit smoking. By contrast, never-smoker 
and non-smoker females exhibited a greater likelihood of increased 
methylation in this site compared to women with any smoking history or who 
were current or ex-smokers. Thus, women with any smoking history seemed 
to have decreased methylation in the MAOB_2 site, while ex-smokers still 
demonstrated lower methylation values than current smokers, as also seen in 





that while smoking affects DNA methylation, methylation together with 
genetic polymorphism also influence smoking behaviour. The relevance of a 
single CpG site in gene transcription may also be crucial in some specific sites. 
This study introduces MAO-B as a potential modifier of smoking 
behaviour both through genetic and epigenetic mechanisms. Importantly, 
each studied CpG site appears to function in an independent and strongly 
gender-associated manner. This refers to the relevance of individual CpGs at a 
specific location to functional consequences in the MAOB gene. It is thus very 
likely that several important methylation sites in MAOB, from the perspective 
of smoking behaviour, still remain to be uncovered.  
Moreover, genetic factors may also play an important role in this context; 
we discovered a novel association between the SLC6A3 30bp VNTR 5R allele 
and very short smoking history. This finding is intriguing, because few 
previous studies have linked the 5R allele to lower gene expression [175] or, 
conversely, the 6R allele to higher SLC6A3 activity leading to lower amount of 
dopamine. This would inhibit the dopaminergic signals at their early stage 
[176].  
According to the results of Study IV, carriage of the 5R allele may be 
particularly helpful in avoiding smoking initiation. This could be explained, 
for example, by the possibility that the impact of the 5R allele on smoking 
behaviour is more likely to result from alterations in other cognitive- or social-
behaviour-related functions dealing more with personality and decision-
making than from nicotine-induced dopamine availability. 
Some studies have speculated that the 40bp VNTR of SLC6A3 may 
influence the protein availability by affecting its expression levels, as it is 
located in the noncoding region of the gene and therefore does not change the 
protein sequence [177]. However, functional studies employing different 
approaches have given controversial results regarding the relations between 
the alleles and protein activity; some studies have not provided any support 
for this polymorphism to have a regulatory role in SLC6A3 expression [175]. 
Nevertheless, in our study, the 40bp VNTR of SLC6A3 was found to be 
associated with several differences in smoking status. For example, we were 
able to give support to the previous observation that carriers of the 9R allele 
are more likely to succeed at quitting smoking than carriers of two 10R alleles 
[63]. This could be explained by increased dopamine transporter 
transcription. By contrast, the 9R allele of the 40bp VNTR was associated with 
a higher risk of nicotine addiction and increased likelihood of becoming a 
regular smoker after trying cigarette smoking.  
These controversial results could be explained by linkage to another 
functional variant allele [175]. Moreover, aside from dopamine availability and 
an increase in reward processing, dopamine has a role in cognitive function, 
which could offer another way to affect smoking behaviour. Since reward 
processing has been proposed to play a key role in adaptive decision making 
[178], individual differences in dopamine processing may affect also the 




In Study IV, significant associations were observed between the mean 
methylation levels of SLC6A3 and smoking phenotype; current smokers were 
2.5 times more likely to have increased methylation levels in SLC6A3 than 
former smokers. The association was also evident among smokers, who had 
reported being unsuccessful in quitting. By contrast, the increased 
methylation was less likely among ex-smokers compared to non-smokers.  
Some previous studies have shown that higher methylation levels in the 
promoter region of SLC6A3 are related to lower gene transcription [178], 
whereas the effect of methylation in the first intron of the gene on protein 
production is more speculative. Therefore, our data could indicate that the 
increased methylation in the first intron of SLC6A3 results in diminished gene 
expression and thus higher dopamine availability. This could make it more 
difficult to quit smoking due to the stronger stimulus in the reward process 
during smoking. Nevertheless, ex-smokers were more likely to have lower 
DNA methylation levels compared to either current or non-smokers, which 
could be partly explained by methylation alterations in response to smoking. 
In Study II, significant connections between DNA methylation and 
CYP2D6 genotypes were discovered, indicating a genotype-dependent 
methylation pattern and an important role of both genetic and epigenetic 
variation in the phenotype formation. However, in Studies III and IV, no 
associations were found between the VNTR polymorphisms or SNPs and DNA 
methylation, even though variations in the SLC6A3 gene-sequence have been 
proposed to affect its epigenetic potential [117] and although we revealed a 
relation between both genetic and epigenetic alterations and smoking status. 
Therefore, the individual differences in DNA methylation pattern may be 
independent of the MAO and SLC6A3 genotypes. However, our recent findings 
indicate that the discovered associations are attributable to local instead of 
global alteration in DNA methylation; methylation patterns differ remarkably 
in specific gene areas (unpublished results). 
6.4 Strengths and weaknesses of the study
This thesis has several strengths not often seen in other comparable studies. 
First, the information about smoking background from the large study 
population is rather comprehensive. The ability to include both genotype and 
methylation-level data in the statistical evaluations is another evident 
advantage. A strength of the thesis is also the rather extensive sample size, 
beneficial for methylation studies and enabling the more reliable detection of 
associations, although this came at the cost of being able to analyse only a 
small proportion of potentially relevant DNA methylation sites of the studied 
genes. Finally, one important advantage of our study setup was the ability to 
study genes located in X chromosome (that is, MAOA and MAOB in Study III), 





This study also has several potential limitations. First, despite the sample 
size, which was extensive for a methylation study, it could have been even 
larger to enable the genetic and methylation data to be better combined and to 
have better power in the statistical analyses. 
 Another weakness could be argued to be the use of total WBC as a source 
of DNA in the epigenetic analyses; in smokers, very different methylation 
patterns have been observed between blood and brain cells [127]. However, 
the reported associations between various common diseases, including mental 
health conditions, and DNA methylation patterns analysed from WBC support 
the usability of this approach [120]. In particular, the methylation status of the 
MAOA promoter in WBC has been suggested to predict brain endophenotype, 
which refers to a phenotype characteristically used with psychiatric disorders 
to describe traits that may be difficult to observe [120]. The use of WBC in 
studies focusing especially on MAOA may thus give more reliable overall 
results than the studies on many other genes.  
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7 CONCLUSIONS AND FUTURE 
PROSPECTS
The results of this thesis indicate that although there are several influential 
factors leading to the development of nicotine addiction, the availability of 
nicotine-induced dopamine in the brain, which affects the level of 
experiencing pleasure, is an important and perhaps crucial part of this process. 
Genetics and epigenetics behind the dopamine turnover thus undoubtedly 
play an important role in both smoking initiation and cessation. Our findings 
support the idea of a nicotine-induced increase in reward processing via 
dopamine availability being behind nicotine addiction. They also point 
towards the importance of genetics and epigenetics of dopamine metabolism 
pathway in the development of nicotine addiction and in the urge to consume 
multiple cigarettes a day. 
First, our results suggest that the inherited CYP2D6-related metabolic 
capacity is strongly related to cigarette consumption, via both genetic and 
epigenetic mechanisms. As CYP2D6 is the most important drug-metabolizing 
enzyme, the numerous CYP2D6 gene variations have a remarkable influence 
on drug response and thereby also on individual dose recommendations. 
Moreover, epigenetic studies could offer both a valuable and a more precise 
evaluation tool for CYP2D6 enzyme activity. 
Second, our results indicate that smoking behaviour is related to the 
genetic and epigenetic profile of MAO genes with considerable individual and 
gender related differences. Because of the observed different impact of specific 
methylation sites in smoking phenotype, the MAO genes should be examined 
carefully, one CpG at time, for even a methylation level of one specific CpG in 
this area seems to have an influence. From this perspective, it is especially 
interesting that the MAOA methylation levels have been shown to change in 
response to psychotherapy and cognitive behavioural therapy (CBT) [139]. 
This intriguing discovery implies a reversibility of DNA methylation in this 
context, which opens whole new possibilities for the treatment of nicotine 
addiction. 
Moreover, we introduced MAOB gene as a novel target for smoking-
related methylation studies and supported the role of its polymorphism in 
smoking behaviour with a strong influence by gender. 
Third, this thesis supports the important role of SLC6A3 in smoking 
behaviour by connecting the variations of VNTR 30bp and 40bp to risk of 
starting and ability to quit smoking, along with discovered higher methylation 
values among current smokers. 
Overall, the use of CYP2D6, MAO, and SLC6A3 methylation as targets 
for both medical and psychotherapy could open new possibilities for the 
treatment of nicotine addiction. In addition to pharmacogenetics, interest in 





epigenetic markers can have a major influence on drug response in cancer and 
schizophrenia patients [180, 181]. Antipsychotics, commonly used medicines 
of schizophrenia patients, have been shown to modify these patients’ 
epigenetic profiles. 
 However, individual differences in methylation profile can influence the 
efficacy of antipsychotics. For example, antipsychotics have been shown to 
alter the methylation levels of the SLC6A4 promoter and a single CpG site 
within the HTR1A promoter in schizophrenia patients. Conversely, 
methylation at the Taq1A locus has been found to affect the response of 
antipsychotic therapy, whereas the IL11 gene methylation has shown to predict 
the response to antidepressants (such as nortriptyline) in schizophrenia 
patients [181]. However, the molecular mechanism behind this remains 
unclear.  
Due to some shared genetic predisposition factors for nicotine addiction, 
some other addictions, and psychiatric disorders, these findings may be of 
great interest and warrant further research in this field. Moreover, since early 
stress events, as well as acute and chronic stresses, can lead to long-term 
epigenetic changes, which may lead to predisposition to addictions and 
psychiatric disorders, psychotherapy could be considered as both a preventive 
action and a useful tool when used in combination with pharmacological drugs 
[182]. 
In summary, since most of the smokers who are highly motived to quit 
tobacco consumption have failed to achieve a long-term abstinence with the 
help of the currently available medical treatment, there obviously are 
significant inter-individual differences in responses to these therapies. 
Therefore, there is an evident need for individually tailored treatment for 
nicotine addiction. Targeting pharmacotherapy to those who are most likely to 
have a better response would be highly cost-effective and would increase the 
success rate of smoking cessation, which would ultimately reduce smoking-
related health problems, illnesses, and death. The results of this thesis provide 
several novel findings and insights which may be helpful in the efforts to reach 





My thesis progressed slowly, yet surely, despite all the changes that I have 
encountered both at work and in my personal life during this fascinating 
journey. I am extremely happy and proud of myself for succeeding in finishing 
the thesis, and I am grateful to many helpful parties; this has truly been a 
collaborative project. 
This thesis was carried out at the Finnish Institute of Occupational 
Health (FIOH). First, I wish to thank Professor Harri Vainio, as well as 
Professor Antti Koivula, the former and present Director General of the FIOH, 
for providing me a position as a young scientist and giving me access to a 
modern DNA laboratory with its excellent facilities. I am grateful to the current 
Director of the Center of Expertise for Occupational Safety, Tommi Alanko, for 
allowing me to maintain access to the institute’s software and data repositories 
after moving to another employer. This was paramount for me to be able to 
finish the thesis. I also want to thank the former team leaders, Kirsti 
Husgafvel-Pursiainen and Harri Alenius, for supporting my studies and 
providing an inspiring working environment. Moreover, I would like to thank 
my financial supporters, the Academy of Finland and the Juho Vainio 
Foundation. 
I would like to thank Professor Juha Partanen, Supervisor for Doctoral 
Programme in Integrative Life Science, and I am also sincerely thankful to 
Professor Pekka Heino at the University of Helsinki for kindly helping me 
through the bureaucracy of the graduation process on a tight schedule. I wish 
to express my gratitude to the official reviewers, Professor Hannu Raunio and 
Docent Merja Auvinen, and the opponent of my dissertation, Professor Janne 
Hukkanen.  
I am most grateful to my supervisor, Docent Ari Hirvonen, who initially 
considered me worth providing with a position as a young scientist and who 
during the following years gave me all the support needed to prepare this 
thesis and encouraged me continuously to take on new challenges. Thank you 
for the priceless help in finishing the thesis on time. I hope you are proud of 
the work we have done together. 
I owe my gratitude to the Russian collaborators, Professor Evgeny 
Imyanitov and Doctor Natalia Mitiushkina, for providing me valuable 
genotyping data to be used in my thesis. I appreciate the effort you made for 
us to achieve all the approved publications. 
I am thankful for the members of my Thesis Committee, Professor 
Hannu Norppa; Docent Tapio Vehmas, and Docent Päivi Piirilä for being 
extremely helpful and flexible, having confidence for my work, and always 
giving me their time when I needed it. I am also very grateful for Hannu’s help 





for her valuable help in statistical matters. Without this help, I would not have 
managed to publish my first work.  
I thank all my co-workers at FIOH, who have contributed to this work 
over the years, especially members of our group, in which it was always easy 
and pleasant to work. I especially acknowledge Miia Antikainen for 
introducing me the field of the genetics of nicotine addiction and for teaching 
me the basics of laboratory work, which encouraged me to continue the great 
work she began. I also thank Mari Kukkonen, for her supervision, advice, and 
help and discussion, and for the unique experience of participating in her 
thesis project and dissertation preparation. I thank Tanja Katovich, whose 
work was very crucial for my work at the laboratory. Even my maternity leave 
did not interrupt the progress of the experimental work, since Tanja finished 
the laboratory analyses with excellent expertise. Satu Hämäläinen, my 
roommate, I thank for precious talks, advice, and help. Finally, I thank Sirpa 
Hyttinen for professionally introducing me to the work at a molecular genetic 
laboratory. 
I was fortunate to get to know several co-workers on the fifth floor and 
beyond, and I appreciate the time spent in lunch and coffee breaks, not to 
mention break exercise. I would like to thank you, Kirsi, for your friendship. 
Thanks also to Susanna, Tuula, Eeva, Laura, Sauli, Henkka, Gerard, Julia, 
Hanna, Sari, Mari, as well as others, all of whom worked together to create a 
friendly, inspiring atmosphere. I am also grateful to many others who have 
encouraged and motivated me in this project by listening and engaging in both 
academic and non-academic conversations with me. 
I am also thankful for my current employer, Woble Helsinki, and its 
managing director Rauno Granath, for giving me the opportunity to finish my 
thesis. I have had chance to develop myself and time to write beyond my work 
at Woble.  
Most of all, I am extremely grateful for my entire family. My children, 
Eetu and Minttu, have brought light to my life with daily laughter. Although 
this would have been much easier if the amount of sleep and time for scientific 
work had been greater, the amount of laughter I have experienced every day 
has never been greater, and this has given me the strength to carry on and push 
forward. Thank you Mom for watching over my lively kids and enabling me to 
focus on finalising my thesis every now and then. None of this would have been 
possible without this support. I would also like to thank my big sisters, Anni 
and Jenni, for providing all the kind and encouraging words when they were 
most needed and for listening to my worries every now and then. Thank you 
Dad for believing in me and my graduation before I did, ever since the day I 
was accepted at university.  
Finally, I want to express my deep gratitude to my dear spouse, Ari, for 
always supporting and believing in me. You have been the only one that I have 
been able to count on, no matter what. Your enormous help and wonderful 
company in scientific planning, writing, and talking, the time we spent at gym, 




preparation of this thesis, has been priceless. This experience has truly been 






1. CDC. Vital signs: current cigarette smoking among adults aged >/=18 years--
United States, 2005-2010. MMWR Morb Mortal Wkly Rep. 2011;60(35):1207-
12. 
2. https://savutonsuomi.fi/en/towards-tobacco-free-finland/timeline/. 
3. Gardner MN, Brandt AM. "The doctors' choice is America's choice": the 






7. Talhout R, Schulz T, Florek E, van Benthem J, Wester P, Opperhuizen A. 
Hazardous compounds in tobacco smoke. Int J Environ Res Public Health. 
2011;8(2):613-28. 
8. https://cancercontrol.cancer.gov/brp/TCRB/monographs/7/m7_5.pdf. 
9. Pappas RS. Toxic elements in tobacco and in cigarette smoke: inflammation and 
sensitization. Metallomics. 2011;3(11):1181-98. 
10. (US) CfDCaP.  How Tobacco Smoke Causes Disease: The Biology and Behavioral 
Basis for Smoking-Attributable Disease: A Report of the Surgeon General. 
Publications and Reports of the Surgeon General. Atlanta (GA)2010. 
11. https://www.cancer.org/cancer/cancer-causes/tobacco-and-cancer/health-
risks-of-smoking-tobacco.html. 
12. Benowitz NL. Nicotine Addiction. N Engl J Med. 2010;362(24):2295-303. 
13. Laniado-Laborin R. Smoking and chronic obstructive pulmonary disease 










18. MacDonald A, Middlekauff HR. Electronic cigarettes and cardiovascular health: 
what do we know so far? Vasc Health Risk Manag. 2019;15:159-74. 
19. Berkowitz L, Schultz BM, Salazar GA, Pardo-Roa C, Sebastian VP, Alvarez-
Lobos MM, et al. Impact of Cigarette Smoking on the Gastrointestinal Tract 
Inflammation: Opposing Effects in Crohn's Disease and Ulcerative Colitis. 




20. Paul CL, Tzelepis F, Boyes AW, D'Este C, Sherwood E, Girgis A. Continued 
smoking after a cancer diagnosis: a longitudinal study of intentions and 
attempts to quit. J Cancer Surviv. 2019;13(5):687-94. 
21. CDC. Vital signs: current cigarette smoking among adults aged >or=18 years --
- United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(35):1135-40. 
22. Fiore M. Treating tobacco use and dependence: 2008 update U.S. Public Health 
Service Clinical Practice Guideline executive summary. Respir Care. 
2008;53(9):1217-22. 
23. Charlton A. Medicinal uses of tobacco in history. J R Soc Med. 2004;97(6):292-
6. 
24. Gold A, Lerman C. Pharmacogenetics of smoking cessation: role of nicotine 
target and metabolism genes. Hum Genet. 2012;131(6):857-76. 
25. Fagerlund MJ, Eriksson LI. Current concepts in neuromuscular transmission. 
Br J Anaesth. 2009;103(1):108-14. 
26. Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X, et al. Variants 
in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry. 
2008;165(9):1163-71. 
27. Benowitz NL. The biology of nicotine dependence: from the 1988 Surgeon 
General's Report to the present and into the future. Nicotine Tob Res. 1999;1 
Suppl 2:S159-63. 
28. Balfour DJ. The role of mesoaccumbens dopamine in nicotine dependence. 
Curr Top Behav Neurosci. 2015;24:55-98. 
29. Quaak M, van Schayck CP, Knaapen AM, van Schooten FJ. Genetic variation as 
a predictor of smoking cessation success. A promising preventive and 
intervention tool for chronic respiratory diseases? Eur Respir J. 
2009;33(3):468-80. 
30. Benowitz NL, Jacob Iii P, Jones RT, Rosenberg J. Interindividual variability in 
the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp 
Ther. 1982;221(2):368-72. 
31. Caporaso NE, Lerman C, Audrain J, Boyd NR, Main D, Issaq HJ, et al. Nicotine 
metabolism and CYP2D6 phenotype in smokers. Cancer Epidemiol Biomarkers 
Prev. 2001;10(3):261-3. 
32. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and 
update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch 
Pharmacol. 2004;369(1):23-37. 
33. Saarikoski ST, Sata F, Husgafvel-Pursiainen K, Rautalahti M, Haukka J, 
Impivaara O, et al. CYP2D6 ultrarapid metabolizer genotype as a potential 
modifier of smoking behaviour. Pharmacogenetics. 2000;10(1):5-10. 
34. Merwar G, Saadabadi A. Nortriptyline.  StatPearls. Treasure Island (FL)2019. 
35. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. 
Antidepressants for smoking cessation. Cochrane Database Syst Rev. 
2014;1:CD000031. 
36. Amos CI, Spitz MR, Cinciripini P. Chipping away at the genetics of smoking 
behavior. Nat Genet. 2010;42(5):366-8. 






38. Fan H, Chu JY. A brief review of short tandem repeat mutation. Genomics 
Proteomics Bioinformatics. 2007;5(1):7-14. 
39. Koreth J, O'Leary JJ, J ODM. Microsatellites and PCR genomic analysis. J 
Pathol. 1996;178(3):239-48. 
40. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of 
up to 1.2 million individuals yield new insights into the genetic etiology of 
tobacco and alcohol use. Nat Genet. 2019;51(2):237-44. 
41. Baker TB, Weiss RB, Bolt D, von Niederhausern A, Fiore MC, Dunn DM, et al. 
Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated 
with multiple nicotine dependence phenotypes. Nicotine Tob Res. 
2009;11(7):785-96. 
42. Caporaso N, Gu F, Chatterjee N, Sheng-Chih J, Yu K, Yeager M, et al. Genome-
wide and candidate gene association study of cigarette smoking behaviors. PloS 
one. 2009;4(2):e4653. 
43. Li MD, Yoon D, Lee JY, Han BG, Niu T, Payne TJ, et al. Associations of variants 
in CHRNA5/A3/B4 gene cluster with smoking behaviors in a Korean 
population. PloS one. 2010;5(8):e12183. 
44. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, et al. Meta-
analysis and imputation refines the association of 15q25 with smoking quantity. 
Nat Genet. 2010;42(5):436-40. 
45. Saccone NL, Wang JC, Breslau N, Johnson EO, Hatsukami D, Saccone SF, et al. 
The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster 
affects risk for nicotine dependence in African-Americans and in European-
Americans. Cancer Res. 2009;69(17):6848-56. 
46. Hamidovic A, Kasberger JL, Young TR, Goodloe RJ, Redline S, Buxbaum SG, et 
al. Genetic variability of smoking persistence in African Americans. Cancer 
Prev Res (Phila). 2011;4(5):729-34. 
47. Breitling LP, Dahmen N, Mittelstrass K, Rujescu D, Gallinat J, Fehr C, et al. 
Association of nicotinic acetylcholine receptor subunit alpha 4 polymorphisms 
with nicotine dependence in 5500 Germans. The Pharmacogenomics J. 
2009;9(4):219-24. 
48. Feng Y, Niu T, Xing H, Xu X, Chen C, Peng S, et al. A common haplotype of the 
nicotine acetylcholine receptor alpha 4 subunit gene is associated with 
vulnerability to nicotine addiction in men. Am J Hum Genet. 2004;75(1):112-
21. 
49. Li MD, Beuten J, Ma JZ, Payne TJ, Lou XY, Garcia V, et al. Ethnic- and gender-
specific association of the nicotinic acetylcholine receptor alpha4 subunit gene 
(CHRNA4) with nicotine dependence. Hum Mol Genet. 2005;14(9):1211-9. 
50. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, et al. 
Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. 
Nat Genet. 2010;42(5):448-53. 
51. Hutchison KE, Allen DL, Filbey FM, Jepson C, Lerman C, Benowitz NL, et al. 
CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. 
Arch Gen Psychiatry. 2007;64(9):1078-86. 
52. Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF, 
et al. Novel genes identified in a high-density genome wide association study 





53. Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA, et 
al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence 
association study targeting 348 candidate genes with 3713 SNPs. Hum Mol 
Genet. 2007;16(1):36-49. 
54. Zeiger JS, Haberstick BC, Schlaepfer I, Collins AC, Corley RP, Crowley TJ, et al. 
The neuronal nicotinic receptor subunit genes (CHRNA6 and CHRNB3) are 
associated with subjective responses to tobacco. Hum Mol Genet. 
2008;17(5):724-34. 
55. Greenbaum L, Kanyas K, Karni O, Merbl Y, Olender T, Horowitz A, et al. Why 
do young women smoke? I. Direct and interactive effects of environment, 
psychological characteristics and nicotinic cholinergic receptor genes. Mol 
Psychiatry. 2006;11(3):312-22, 223. 
56. Lou XY, Ma JZ, Payne TJ, Beuten J, Crew KM, Li MD. Gene-based analysis 
suggests association of the nicotinic acetylcholine receptor beta1 subunit 
(CHRNB1) and M1 muscarinic acetylcholine receptor (CHRM1) with 
vulnerability for nicotine dependence. Hum Genet. 2006;120(3):381-9. 
57. Ma Y, Wang M, Yuan W, Su K, Li MD. The significant association of Taq1A 
genotypes in DRD2/ANKK1 with smoking cessation in a large-scale meta-
analysis of Caucasian populations. Transl Psychiatry. 2015;5:e686. 
58. Noble EP, St Jeor ST, Ritchie T, Syndulko K, St Jeor SC, Fitch RJ, et al. D2 
dopamine receptor gene and cigarette smoking: a reward gene? Med 
Hypotheses. 1994;42(4):257-60. 
59. Comings DE, Gade R, Wu S, Chiu C, Dietz G, Muhleman D, et al. Studies of the 
potential role of the dopamine D1 receptor gene in addictive behaviors. Mol 
Psychiatry. 1997;2(1):44-56. 
60. Laucht M, Becker K, El-Faddagh M, Hohm E, Schmidt MH. Association of the 
DRD4 exon III polymorphism with smoking in fifteen-year-olds: a mediating 
role for novelty seeking? J Am Acad Child Adolesc Psychiatry. 2005;44(5):477-
84. 
61. Shields PG, Lerman C, Audrain J, Bowman ED, Main D, Boyd NR, et al. 
Dopamine D4 receptors and the risk of cigarette smoking in African-Americans 
and Caucasians. Cancer Epidemiol Biomarkers Prev. 1998;7(6):453-8. 
62. Sullivan PF, Neale MC, Silverman MA, Harris-Kerr C, Myakishev MV, Wormley 
B, et al. An association study of DRD5 with smoking initiation and progression 
to nicotine dependence. Am J Med Genet. 2001;105(3):259-65. 
63. Herman AI, DeVito EE, Jensen KP, Sofuoglu M. Pharmacogenetics of nicotine 
addiction: role of dopamine. Pharmacogenomics. 2014;15(2):221-34. 
64. Lerman C, Caporaso NE, Audrain J, Main D, Bowman ED, Lockshin B, et al. 
Evidence suggesting the role of specific genetic factors in cigarette smoking. 
Health Psychol. 1999;18(1):14-20. 
65. Perkins KA, Lerman C, Grottenthaler A, Ciccocioppo MM, Milanak M, Conklin 
CA, et al. Dopamine and opioid gene variants are associated with increased 
smoking reward and reinforcement owing to negative mood. Behav Pharmacol. 
2008;19(5-6):641-9. 
66. Sieminska A, Buczkowski K, Jassem E, Niedoszytko M, Tkacz E. Influences of 
polymorphic variants of DRD2 and SLC6A3 genes, and their combinations on 





67. Ito H, Hamajima N, Matsuo K, Okuma K, Sato S, Ueda R, et al. Monoamine 
oxidase polymorphisms and smoking behaviour in Japanese. 
Pharmacogenetics. 2003;13(2):73-9. 
68. Lewis A, Miller JH, Lea RA. Monoamine oxidase and tobacco dependence. 
Neurotoxicology. 2007;28(1):182-95. 
69. Ray R, Jepson C, Patterson F, Strasser A, Rukstalis M, Perkins K, et al. 
Association of OPRM1 A118G variant with the relative reinforcing value of 
nicotine. Psychopharmacology (Berl). 2006;188(3):355-63. 
70. Anney RJ, Olsson CA, Lotfi-Miri M, Patton GC, Williamson R. Nicotine 
dependence in a prospective population-based study of adolescents: the 
protective role of a functional tyrosine hydroxylase polymorphism. 
Pharmacogenetics. 2004;14(2):73-81. 
71. Ma JZ, Beuten J, Payne TJ, Dupont RT, Elston RC, Li MD. Haplotype analysis 
indicates an association between the DOPA decarboxylase (DDC) gene and 
nicotine dependence. Hum Mol Genet. 2005;14(12):1691-8. 
72. Yu Y, Panhuysen C, Kranzler HR, Hesselbrock V, Rounsaville B, Weiss R, et al. 
Intronic variants in the dopa decarboxylase (DDC) gene are associated with 
smoking behavior in European-Americans and African-Americans. Hum Mol 
Genet. 2006;15(14):2192-9. 
73. Zhang H, Ye Y, Wang X, Gelernter J, Ma JZ, Li MD. DOPA decarboxylase gene 
is associated with nicotine dependence. Pharmacogenomics. 2006;7(8):1159-
66. 
74. Tobacco, Genetics C. Genome-wide meta-analyses identify multiple loci 
associated with smoking behavior. Nat Genet. 2010;42(5):441-7. 
75. Lerman C, Caporaso NE, Bush A, Zheng YL, Audrain J, Main D, et al. 
Tryptophan hydroxylase gene variant and smoking behavior. Am J Med Genet. 
2001;105(6):518-20. 
76. Reuter M, Hennig J. Pleiotropic effect of the TPH A779C polymorphism on 
nicotine dependence and personality. Am J Med Genet B Neuropsychiatr 
Genet. 2005;134B(1):20-4. 
77. Reuter M, Hennig J, Amelang M, Montag C, Korkut T, Hueweler A, et al. The 
role of the TPH1 and TPH2 genes for nicotine dependence: a genetic association 
study in two different age cohorts. Neuropsychobiology. 2007;56(1):47-54. 
78. Sullivan PF, Jiang Y, Neale MC, Kendler KS, Straub RE. Association of the 
tryptophan hydroxylase gene with smoking initiation but not progression to 
nicotine dependence. Am J Med Genet. 2001;105(5):479-84. 
79. Chu SL, Xiao D, Wang C, Jing H. Association between 5-hydroxytryptamine 
transporter gene-linked polymorphic region and smoking behavior in Chinese 
males. Chin Med J (Engl). 2009;122(12):1365-8. 
80. Ishikawa H, Ohtsuki T, Ishiguro H, Yamakawa-Kobayashi K, Endo K, Lin YL, et 
al. Association between serotonin transporter gene polymorphism and smoking 
among Japanese males. Cancer Epidemiol Biomarkers Prev. 1999;8(9):831-3. 
81. Lerman C, Caporaso NE, Audrain J, Main D, Boyd NR, Shields PG. Interacting 
effects of the serotonin transporter gene and neuroticism in smoking practices 
and nicotine dependence. Mol Psychiatry. 2000;5(2):189-92. 
82. Iwahashi K, Waga C, Takimoto T. Whole deletion of CYP2A6 gene 





83. Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic 
variation for smoking behaviors and nicotine dependence. Clin Pharmacol 
Ther. 2005;77(3):145-58. 
84. Mwenifumbo JC, Tyndale RF. Genetic variability in CYP2A6 and the 
pharmacokinetics of nicotine. Pharmacogenomics. 2007;8(10):1385-402. 
85. Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces 
smoking. Nature. 1998;393(6687):750. 
86. Audrain-McGovern J, Al Koudsi N, Rodriguez D, Wileyto EP, Shields PG, 
Tyndale RF. The role of CYP2A6 in the emergence of nicotine dependence in 
adolescents. Pediatrics. 2007;119(1):e264-74. 
87. Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M, et al. 
Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking 
behavior and tobacco-related lung cancer risk in male Japanese smokers. 
Carcinogenesis. 2004;25(12):2451-8. 
88. Kubota T, Nakajima-Taniguchi C, Fukuda T, Funamoto M, Maeda M, Tange E, 
et al. CYP2A6 polymorphisms are associated with nicotine dependence and 
influence withdrawal symptoms in smoking cessation. Pharmacogenomics J. 
2006;6(2):115-9. 
89. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. 
Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine 
levels from and usage of nicotine replacement therapy. Mol Psychiatry. 
2006;11(4):400-9. 
90. Minematsu N, Nakamura H, Iwata M, Tateno H, Nakajima T, Takahashi S, et 
al. Association of CYP2A6 deletion polymorphism with smoking habit and 
development of pulmonary emphysema. Thorax. 2003;58(7):623-8. 
91. Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers EM, et al. Duplications 
and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects 
on smoking. Mol Pharmacol. 2000;58(4):747-55. 
92. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in 
CYP2A6 and association of genetically slow nicotine metabolism and smoking 
in adult Caucasians. Pharmacogenetics. 2004;14(9):615-26. 
93. Tyndale RF, Pianezza ML, Sellers EM. A common genetic defect in nicotine 
metabolism decreases risk for dependence and lowers cigarette consumption. 
Nicotine Tob Res. 1999;1 Suppl 2:S63-7; discussion S9-70. 
94. Gu DF, Hinks LJ, Morton NE, Day IN. The use of long PCR to confirm three 
common alleles at the CYP2A6 locus and the relationship between genotype and 
smoking habit. Ann Hum Genet. 2000;64(Pt 5):383-90. 
95. Nussbaum J, Xu Q, Payne TJ, Ma JZ, Huang W, Gelernter J, et al. Significant 
association of the neurexin-1 gene (NRXN1) with nicotine dependence in 
European- and African-American smokers. Hum Mol Genet. 2008;17(11):1569-
77. 
96. Perez-Rubio G, Perez-Rodriguez ME, Fernandez-Lopez JC, Ramirez-Venegas A, 
Garcia-Colunga J, Avila-Moreno F, et al. SNPs in NRXN1 and CHRNA5 are 
associated to smoking and regulation of GABAergic and glutamatergic 
pathways. Pharmacogenomics. 2016;17(10):1145-58. 
97. Lang UE, Sander T, Lohoff FW, Hellweg R, Bajbouj M, Winterer G, et al. 
Association of the met66 allele of brain-derived neurotrophic factor (BDNF) 





98. Ohmoto M, Takahashi T. Effect of genetic polymorphism of brain-derived 
neurotrophic factor and serotonin transporter on smoking phenotypes: A pilot 
study of Japanese participants. Heliyon. 2019;5(2):e01234. 
99. Rajabi A, Khosravi P, Motevalian SA, Farjam M, Shojaei A. The association 
between polymorphism of the BDNF gene and cigarette smoking in the Iranian 
population. J Gene Med. 2018;20(10-11):e3052. 
100. Zhang XY, Chen DC, Tan YL, Luo X, Zuo L, Lv MH, et al. Smoking and BDNF 
Val66Met polymorphism in male schizophrenia: a case-control study. J 
Psychiatr Res. 2015;60:49-55. 
101. King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, et al. 
Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion 
in Placebo-Controlled Clinical Trials. Neuropsychopharmacology. 
2012;37(3):641-50. 
102. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. 
Nicotinic acetylcholine receptor variation and response to smoking cessation 
therapies. Pharmacogenet Genomics. 2013;23(2):94-103. 
103. Munafò MR, Johnstone EC, Walther D, Uhl GR, Murphy MFG, Aveyard P. 
CHRNA3 rs1051730 Genotype and Short-Term Smoking Cessation. Nicotine 
Tob Res. 2011;13(10):982-8. 
104. Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD, et al. Nicotinic 
acetylcholine receptor β2 subunit gene implicated in a systems-based candidate 
gene study of smoking cessation. Hum Mol Genet. 2008;17(18):2834-48. 
105. Perkins KA, Lerman C, Mercincavage M, Fonte CA, Briski JL. Nicotinic 
acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to 
quit smoking in response to nicotine patch. Cancer Epidemiol Biomarkers 
Prev. 2009;18(10):2608-12. 
106. David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, 
Munafò MR, et al. Pharmacogenetic clinical trial of sustained-release 
bupropion for smoking cessation. Nicotine Tob Res. 2007;9(8):821-33. 
107. Chen LS, Bloom AJ, Baker TB, Smith SS, Piper ME, Martinez M, et al. 
Pharmacotherapy effects on smoking cessation vary with nicotine metabolism 
gene (CYP2A6). Addiction. 2014;109(1):128-37. 
108. Akrodou YM. CYP2A6 Polymorphisms May Strengthen Individualized 
Treatment for Nicotine Dependence. Scientifica (Cairo). 2015;2015:491514. 
109. Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, et al. CYP2B6 
Genotype Alters Abstinence Rates in a Bupropion Smoking Cessation Trial. 
Biological Psychiatry. 2007;62(6):635-41. 
110. Tomaz PRX, Kajita MS, Santos JR, Scholz J, Abe TO, Gaya PV, et al. 
Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success 
in patients treated with varenicline. Eur J Clin Pharmacol. 2019;75(11):1541-5. 
111. Colilla S, Lerman C, Shields PG, Jepson C, Rukstalis M, Berlin J, et al. 
Association of catechol-O-methyltransferase with smoking cessation in two 
independent studies of women. Pharmacogenet Genomics. 2005;15(6):393-8. 
112. Johnstone EC, Elliot KM, David SP, Murphy MF, Walton RT, Munafo MR. 
Association of COMT Val108/158Met genotype with smoking cessation in a 





113. Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, Ton CC, et al. Dopamine 
receptor DRD2 genotype and smoking cessation outcome following treatment 
with bupropion SR. Pharmacogenomics J. 2005;5(1):21-9. 
114. Chang SC, Koenen KC, Galea S, Aiello AE, Soliven R, Wildman DE, et al. 
Molecular variation at the SLC6A3 locus predicts lifetime risk of PTSD in the 
Detroit Neighborhood Health Study. PloS one. 2012;7(6):e39184. 
115. O'Loughlin J, Sylvestre MP, Labbe A, Low NC, Roy-Gagnon MH, Dugas EN, et 
al. Genetic variants and early cigarette smoking and nicotine dependence 
phenotypes in adolescents. PloS one. 2014;9(12):e115716. 
116. Guindalini C, Howard M, Haddley K, Laranjeira R, Collier D, Ammar N, et al. A 
dopamine transporter gene functional variant associated with cocaine abuse in 
a Brazilian sample. Proc Natl Acad Sci U S A. 2006;103(12):4552-7. 
117. Shumay E, Fowler JS, Volkow ND. Genomic features of the human dopamine 
transporter gene and its potential epigenetic States: implications for phenotypic 
diversity. PloS one. 2010;5(6):e11067. 
118. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, et al. 
Inhibition of monoamine oxidase B in the brains of smokers. Nature. 
1996;379(6567):733-6. 
119. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, et al. Brain 
monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S 
A. 1996;93(24):14065-9. 
120. Shumay E, Logan J, Volkow ND, Fowler JS. Evidence that the methylation state 
of the monoamine oxidase A (MAOA) gene predicts brain activity of MAO A 
enzyme in healthy men. Epigenetics. 2012;7(10):1151-60. 
121. Craig IW. The importance of stress and genetic variation in human aggression. 
Bioessays. 2007;29(3):227-36. 
122. McDermott R, Tingley D, Cowden J, Frazzetto G, Johnson DD. Monoamine 
oxidase A gene (MAOA) predicts behavioral aggression following provocation. 
Proc Natl Acad Sci U S A. 2009;106(7):2118-23. 
123. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: 
regulation of gene expression, enzyme activities, and impact of genetic 
variation. Pharmacol Ther. 2013;138(1):103-41. 
124. Hodgson K, Tansey K, Dernovsek MZ, Hauser J, Henigsberg N, Maier W, et al. 
Genetic differences in cytochrome P450 enzymes and antidepressant treatment 
response. J Psychopharmacol. 2014;28(2):133-41. 
125. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom 
Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance 
Questionnaire. Br J Addict. 1991;86(9):1119-27. 
126. Nestler EJ. Epigenetic mechanisms of drug addiction. Neuropharmacology. 
2014;76 Pt B:259-68. 
127. Lee KW, Pausova Z. Cigarette smoking and DNA methylation. Front Genet. 
2013;4:132. 
128. Deaton AM, Webb S, Kerr AR, Illingworth RS, Guy J, Andrews R, et al. Cell type-
specific DNA methylation at intragenic CpG islands in the immune system. 
Genome Res. 2011;21(7):1074-86. 
129. Launay JM, Del Pino M, Chironi G, Callebert J, Peoc'h K, Megnien JL, et al. 
Smoking induces long-lasting effects through a monoamine-oxidase epigenetic 





130. Wan ES, Qiu W, Baccarelli A, Carey VJ, Bacherman H, Rennard SI, et al. 
Cigarette smoking behaviors and time since quitting are associated with 
differential DNA methylation across the human genome. Hum Mol Genet. 
2012;21(13):3073-82. 
131. Satta R, Maloku E, Zhubi A, Pibiri F, Hajos M, Costa E, et al. Nicotine decreases 
DNA methyltransferase 1 expression and glutamic acid decarboxylase 67 
promoter methylation in GABAergic interneurons. Proc Natl Acad Sci U S A. 
2008;105(42):16356-61. 
132. Wang T, Chen M, Liu L, Cheng H, Yan YE, Feng YH, et al. Nicotine induced CpG 
methylation of Pax6 binding motif in StAR promoter reduces the gene 
expression and cortisol production. Toxicol Appl Pharmacol. 2011;257(3):328-
37. 
133. Kaur G, Begum R, Thota S, Batra S. A systematic review of smoking-related 
epigenetic alterations. Arch Toxicol. 2019;93(10):2715-40. 
134. Chen Y, Zhang J, Zhang L, Shen Y, Xu Q. Effects of MAOA promoter 
methylation on susceptibility to paranoid schizophrenia. Hum Genet. 
2012;131(7):1081-7. 
135. Dammann G, Teschler S, Haag T, Altmuller F, Tuczek F, Dammann RH. 
Increased DNA methylation of neuropsychiatric genes occurs in borderline 
personality disorder. Epigenetics. 2011;6(12):1454-62. 
136. Kordi-Tamandani DM, Sahranavard R, Torkamanzehi A. Analysis of 
association between dopamine receptor genes' methylation and their 
expression profile with the risk of schizophrenia. Psychiatr Genet. 
2013;23(5):183-7. 
137. Ziegler C, Domschke K. Epigenetic signature of MAOA and MAOB genes in 
mental disorders. J Neural Transm (Vienna). 2018;125(11):1581-8. 
138. Checknita D, Maussion G, Labonte B, Comai S, Tremblay RE, Vitaro F, et al. 
Monoamine oxidase A gene promoter methylation and transcriptional 
downregulation in an offender population with antisocial personality disorder. 
Br J Psychiatry. 2015;206(3):216-22. 
139. Ziegler C, Richter J, Mahr M, Gajewska A, Schiele MA, Gehrmann A, et al. 
MAOA gene hypomethylation in panic disorder-reversibility of an epigenetic 
risk pattern by psychotherapy. Transl Psychiatry. 2016;6:e773. 
140. Domschke K, Tidow N, Schwarte K, Ziegler C, Lesch KP, Deckert J, et al. 
Pharmacoepigenetics of depression: no major influence of MAO-A DNA 
methylation on treatment response. J Neural Transm (Vienna). 
2015;122(1):99-108. 
141. Frieling H, Romer KD, Scholz S, Mittelbach F, Wilhelm J, De Zwaan M, et al. 
Epigenetic dysregulation of dopaminergic genes in eating disorders. Int J Eat 
Disord. 2010;43(7):577-83. 
142. Wiers CE, Shumay E, Volkow ND, Frieling H, Kotsiari A, Lindenmeyer J, et al. 
Effects of depressive symptoms and peripheral DAT methylation on neural 
reactivity to alcohol cues in alcoholism. Transl Psychiatry. 2015;5:e648. 
143. Maze I, Nestler EJ. The epigenetic landscape of addiction. Ann N Y Acad Sci. 
2011;1216:99-113. 
144. McQuown SC, Wood MA. Epigenetic regulation in substance use disorders. 




145. Philibert RA, Gunter TD, Beach SR, Brody GH, Madan A. MAOA methylation is 
associated with nicotine and alcohol dependence in women. Am J Med Genet B 
Neuropsychiatr Genet. 2008;147B(5):565-70. 
146. Philibert RA, Beach SR, Gunter TD, Brody GH, Madan A, Gerrard M. The effect 
of smoking on MAOA promoter methylation in DNA prepared from 
lymphoblasts and whole blood. Am J Med Genet B Neuropsychiatr Genet. 
2010;153B(2):619-28. 
147. Xu Q, Ma JZ, Payne TJ, Li MD. Determination of Methylated CpG Sites in the 
Promoter Region of Catechol-O-Methyltransferase (COMT) and their 
Involvement in the Etiology of Tobacco Smoking. Front Psychiatry. 2010;1:16. 
148. Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobacco-smoking-
related differential DNA methylation: 27K discovery and replication. Am J Hum 
Genet. 2011;88(4):450-7. 
149. Elliott HR, Tillin T, McArdle WL, Ho K, Duggirala A, Frayling TM, et al. 
Differences in smoking associated DNA methylation patterns in South Asians 
and Europeans. Clin Epigenetics. 2014;6(1):4. 
150. Philibert RA, Beach SR, Lei MK, Brody GH. Changes in DNA methylation at the 
aryl hydrocarbon receptor repressor may be a new biomarker for smoking. Clin 
Epigenetics. 2013;5(1):19. 
151. Shenker NS, Polidoro S, van Veldhoven K, Sacerdote C, Ricceri F, Birrell MA, et 
al. Epigenome-wide association study in the European Prospective 
Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic 
loci associated with smoking. Hum Mol Genet. 2013;22(5):843-51. 
152. Sun YV, Smith AK, Conneely KN, Chang Q, Li W, Lazarus A, et al. Epigenomic 
association analysis identifies smoking-related DNA methylation sites in 
African Americans. Hum Genet. 2013;132(9):1027-37. 
153. Zaghlool SB, Al-Shafai M, Al Muftah WA, Kumar P, Falchi M, Suhre K. 
Association of DNA methylation with age, gender, and smoking in an Arab 
population. Clin Epigenetics. 2015;7:6. 
154. Zeilinger S, Kuhnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, et al. 
Tobacco smoking leads to extensive genome-wide changes in DNA methylation. 
PloS one. 2013;8(5):e63812. 
155. Fasanelli F, Baglietto L, Ponzi E, Guida F, Campanella G, Johansson M, et al. 
Hypomethylation of smoking-related genes is associated with future lung 
cancer in four prospective cohorts. Nat Commun. 2015;6:10192. 
156. Koks S, Koks G. Activation of GPR15 and its involvement in the biological effects 
of smoking. Exp Biol Med (Maywood). 2017;242(11):1207-12. 
157. Schiele MA, Ziegler C, Kollert L, Katzorke A, Schartner C, Busch Y, et al. 
Plasticity of Functional MAOA Gene Methylation in Acrophobia. Int J 
Neuropsychopharmacol. 2018;21(9):822-7. 
158. Melas PA, Forsell Y. Hypomethylation of MAOA's first exon region in 
depression: a replication study. Psychiatry Res. 2015;226(1):389-91. 
159. Melas PA, Wei Y, Wong CC, Sjoholm LK, Aberg E, Mill J, et al. Genetic and 
epigenetic associations of MAOA and NR3C1 with depression and childhood 
adversities. Int J Neuropsychopharmacol. 2013;16(7):1513-28. 
160. Ziegler C, Wolf C, Schiele MA, Feric Bojic E, Kucukalic S, Sabic Dzananovic E, 
et al. Monoamine Oxidase A Gene Methylation and Its Role in Posttraumatic 
Stress Disorder: First Evidence from the South Eastern Europe (SEE)-PTSD 





161. Qazi TJ, Quan Z, Mir A, Qing H. Epigenetics in Alzheimer's Disease: Perspective 
of DNA Methylation. Mol Neurobiol. 2018;55(2):1026-44. 
162. Mullenbach R, Lagoda PJ, Welter C. An efficient salt-chloroform extraction of 
DNA from blood and tissues. Trends Genet. 1989;5(12):391. 
163. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, et al. 
Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and 
displays a VNTR. Genomics. 1992;14(4):1104-6. 
164. Eriksson S, Berg LM, Wadelius M, Alderborn A. Cytochrome p450 genotyping 
by multiplexed real-time dna sequencing with pyrosequencing technology. 
Assay Drug Dev Technol. 2002;1(1 Pt 1):49-59. 
165. Deckert J, Catalano M, Syagailo YV, Bosi M, Okladnova O, Di Bella D, et al. 
Excess of high activity monoamine oxidase A gene promoter alleles in female 
patients with panic disorder. Hum Mol Genet. 1999;8(4):621-4. 
166. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine 
oxidase A gene promoter. Hum Genet. 1998;103(3):273-9. 
167. Miksys S, Tyndale RF. Cytochrome P450-mediated drug metabolism in the 
brain. J Psychiatry Neurosci. 2013;38(3):152-63. 
168. Boks MP, Derks EM, Weisenberger DJ, Strengman E, Janson E, Sommer IE, et 
al. The relationship of DNA methylation with age, gender and genotype in twins 
and healthy controls. PloS one. 2009;4(8):e6767. 
169. Kerkel K, Spadola A, Yuan E, Kosek J, Jiang L, Hod E, et al. Genomic surveys 
by methylation-sensitive SNP analysis identify sequence-dependent allele-
specific DNA methylation. Nat Genet. 2008;40(7):904-8. 
170. Bromek E, Haduch A, Daniel WA. The ability of cytochrome P450 2D isoforms 
to synthesize dopamine in the brain: An in vitro study. Eur J Pharmacol. 
2010;626(2-3):171-8. 
171. Niwa T, Yanai M, Matsumoto M, Shizuku M. Effect of Cytochrome P450 (CYP) 
2D6 Genetic Polymorphism on the Inhibitory Action of Antidepressants on 
CYP2D6-Mediated Dopamine Formation from p-Tyramine. J Pharm Pharm 
Sci. 2018;21(1):135-42. 
172. Penas LEM, Dorado P, Pacheco R, Gonzalez I, A LL. Relation between CYP2D6 
genotype, personality, neurocognition and overall psychopathology in healthy 
volunteers. Pharmacogenomics. 2009;10(7):1111-20. 
173. Roberts RL, Luty SE, Mulder RT, Joyce PR, Kennedy MA. Association between 
cytochrome P450 2D6 genotype and harm avoidance. Am J Med Genet B 
Neuropsychiatr Genet. 2004;127B(1):90-3. 
174. Balciuniene J, Emilsson L, Oreland L, Pettersson U, Jazin E. Investigation of 
the functional effect of monoamine oxidase polymorphisms in human brain. 
Hum Genet. 2002;110(1):1-7. 
175. Pinsonneault JK, Han DD, Burdick KE, Kataki M, Bertolino A, Malhotra AK, et 
al. Dopamine transporter gene variant affecting expression in human brain is 
associated with bipolar disorder. Neuropsychopharmacology. 
2011;36(8):1644-55. 
176. Lundwall RA, Dannemiller JL. Genetic contributions to attentional response 
time slopes across repeated trials. BMC Neurosci. 2015;16:66. 
177. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M, et al. 
Increased dopamine transporter availability associated with the 9-repeat allele 




178. Muench C, Wiers CE, Cortes CR, Momenan R, Lohoff FW. Dopamine 
Transporter Gene Methylation is Associated with Nucleus Accumbens 
Activation During Reward Processing in Healthy but not Alcohol-Dependent 
Individuals. Alcohol Clin Exp Res. 2018;42(1):21-31. 
179. Klebaner D, Huang Y, Hui Q, Taylor JY, Goldberg J, Vaccarino V, et al. X 
chromosome-wide analysis identifies DNA methylation sites influenced by 
cigarette smoking. Clin Epigenetics. 2016;8:20. 
180. Lopez-Camarillo C, Gallardo-Rincon D, Alvarez-Sanchez ME, Marchat LA. 
Pharmaco-epigenomics: On the Road of Translation Medicine. Adv Exp Med 
Biol. 2019;1168:31-42. 
181. Ovenden ES, McGregor NW, Emsley RA, Warnich L. DNA methylation and 
antipsychotic treatment mechanisms in schizophrenia: Progress and future 
directions. Prog Neuropsychopharmacol Biol Psychiatry. 2018;81:38-49. 
182. Cadet JL. Epigenetics of Stress, Addiction, and Resilience: Therapeutic 
Implications. Mol Neurobiol. 2016;53(1):545-60. 
 
